[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 365
1. Coco DP, Hirsch MS, Hornick JL: Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract. Am J Surg Pathol; 2009 Dec;33(12):1795-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smoothelin is a specific marker for smooth muscle neoplasms of the gastrointestinal tract.
  • Smoothelin is a smooth muscle-specific cytoskeletal protein exclusively found in differentiated smooth muscle cells.
  • This contrasts with other smooth muscle proteins (eg, h-caldesmon, alpha-smooth muscle actin, desmin, smooth muscle myosin), which are expressed in proliferative (early) stages of smooth muscle development and occasionally in other cell types (striated muscle, myofibroblasts, myoepithelial cells, pericytes).
  • Smoothelin has been shown to be expressed predominantly in visceral smooth muscle and to a lesser extent in vascular smooth muscle.
  • Smoothelin expression in mesenchymal tumors of the gastrointestinal (GI) tract has not been evaluated earlier.
  • The purpose of this study was to determine whether immunostaining for smoothelin could help distinguish smooth muscle neoplasms from their morphologic mimics, particularly KIT-negative gastrointestinal stromal tumors (GISTs), desmin-positive GISTs, and desmoid fibromatosis.
  • A total of 150 mesenchymal neoplasms of the GI tract, abdominal cavity, and retroperitoneum were retrieved from consult and surgical pathology archives, including 54 GISTs (8 KIT-negative; 13 desmin-positive), 17 GI leiomyosarcomas (LMS), 11 GI mural leiomyomas, 13 leiomyomas of the muscularis mucosae, 12 gastric schwannomas, 15 inflammatory myofibroblastic tumors, 9 cases of mesenteric desmoid fibromatosis, 10 dedifferentiated liposarcomas, and 9 malignant peripheral nerve sheath tumors.
  • Cytoplasmic expression of smoothelin was present in all 24 (100%) benign smooth muscle tumors (mural leiomyomas and leiomyomas of the muscularis mucosae).
  • None of the GISTs, desmoid tumors, inflammatory myofibroblastic tumors, schwannomas, dedifferentiated liposarcomas, or malignant peripheral nerve sheath tumors showed cytoplasmic reactivity for smoothelin.
  • Nuclear expression of smoothelin was not detected in any of the other tumor types examined.
  • Aberrant nuclear expression is common in GI LMS and may also be seen in GISTs, especially epithelioid and mixed-type tumors.
  • These findings suggest that the extent and pattern of smoothelin expression may help differentiate between benign and malignant mesenchymal tumors of the GI tract, and may be useful in distinguishing leiomyomas from KIT-negative and/or desmin-positive GISTs.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytoskeletal Proteins / analysis. Gastrointestinal Neoplasms / chemistry. Muscle Proteins / analysis. Smooth Muscle Tumor / chemistry
  • [MeSH-minor] Cell Differentiation. Cell Nucleus / chemistry. Cytoplasm / chemistry. Desmin / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Neoplasm Staging. Predictive Value of Tests. Proto-Oncogene Proteins c-kit / analysis. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950405.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Desmin; 0 / Muscle Proteins; 0 / SMTN protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


2. Ip PP, Tse KY, Tam KF: Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol; 2010 Mar;17(2):91-112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
  • Uterine smooth muscle tumors are classified according to their morphologic features that include architecture, growth pattern, cellular characteristics and constituents of the intercellular stroma.
  • While terminologies used for the pathologic diagnosis of various subtypes may be eloquent and histologically accurate, some of these are confusing for the clinician and may also be open to interpretation by different pathologists: the labeling of atypical leiomyomas epitomizes this intricate system.
  • Clinically, it is probably more useful to classify them as either tumors with or tumors without recurrent and/or metastatic potential.
  • The term "atypical leiomyoma" has been used to label tumors that have a low risk of recurrence and is synonymous with benign tumors.
  • Variants of benign uterine smooth muscle tumors, such as mitotically active leiomyoma, cellular and highly cellular leiomyoma, epithelioid leiomyoma, and myxoid leiomyoma each have distinctive hallmarks that enable subclassification.
  • Tumors that have a dissecting growth pattern, with or without extrauterine extension, may mimic malignancy both grossly and microscopically.
  • The current review discusses the pathologic diagnosis of and terminology applied to selected variants of uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas with emphasis on unusual reported features that may indicate malignancy.
  • This includes an update on uterine smooth muscle tumor of uncertain malignant potential (STUMP), intravenous leiomyomatosis, benign metastasizing leiomyoma, and diffuse leiomyomatosis.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Leiomyoma / pathology. Leiomyoma, Epithelioid / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179432.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 156
  •  go-up   go-down


3. Salamanca J, Massa DS: EBV-associated hepatic smooth muscle tumor after lung transplantation: report of a case and review of the literature. J Heart Lung Transplant; 2009 Nov;28(11):1217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated hepatic smooth muscle tumor after lung transplantation: report of a case and review of the literature.
  • Post-transplant smooth muscle tumors (PTSMTs) are a rare and recently recognized neoplasm associated with Epstein-Barr virus (EBV).
  • We describe the clinicopathologic, immunohistochemical and molecular features of a new case of EBV-associated PTSMT arising in the liver of a 55-year-old lung transplant recipient for lymphangioleiomyomatosis.
  • To our knowledge, this is the third smooth muscle tumor (the second one proved to be associated with EBV) after lung transplantation.
  • The 2 previous cases are reviewed and the differential diagnosis is also discussed.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Liver Neoplasms / virology. Lung Transplantation / adverse effects. Lymphangioleiomyomatosis / diagnosis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783183.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Delides A, Petrides N, Banis K: Multifocal adult rhabdomyoma of the head and neck: a case report and literature review. Eur Arch Otorhinolaryngol; 2005 Jun;262(6):504-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult extracardiac rhabdomyomas are rare benign skeletal muscle tumors that most commonly present in the head and neck region.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Neoplasms, Second Primary / surgery. Rhabdomyoma / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1993 Apr;24(4):448-51 [8491485.001]
  • [Cites] Laryngoscope. 1976 Jan;86(1):98-103 [1256209.001]
  • [Cites] Int J Oral Maxillofac Surg. 1991 Aug;20(4):201-3 [1940496.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Mar;119(3):350-2 [8435178.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Jul;56(1):76-8 [6576314.001]
  • [Cites] Arch Otolaryngol. 1981 Mar;107(3):175-8 [7469907.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1993;250(5):308-11 [8217136.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):721-8 [1530111.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):1011-8 [1200093.001]
  • [Cites] J Laryngol Otol. 1994 Aug;108(8):713-5 [7930931.001]
  • [Cites] J Laryngol Otol. 1988 Dec;102(12):1185-8 [3225536.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):780-9 [7397640.001]
  • [Cites] Cancer. 1978 Oct;42(4):1983-8 [709543.001]
  • [Cites] Arch Pathol Lab Med. 1983 Dec;107(12):638-42 [6357142.001]
  • [Cites] J Neurosurg. 2000 Oct;93(4):715 [11014556.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1998 May-Jun;60(3):178-80 [9579365.001]
  • [Cites] Acta Otolaryngol. 1974 Nov-Dec;78(5-6):458-64 [4375402.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000;257(1):24-6 [10664040.001]
  • [Cites] Am J Clin Pathol. 1969 Jul;52(1):37-41 [5789482.001]
  • [Cites] Head Neck. 1992 Sep-Oct;14 (5):395-400 [1399575.001]
  • [Cites] Am J Dermatopathol. 2000 Jun;22(3):264-7 [10871072.001]
  • [Cites] Acta Cytol. 2000 Mar-Apr;44(2):223-6 [10740610.001]
  • [Cites] Pathol Res Pract. 1988 Aug;183(4):512-8 [3054829.001]
  • [Cites] Arch Otolaryngol. 1969 Oct;90(4):489-91 [5806075.001]
  • [Cites] Am J Dermatopathol. 1990 Oct;12(5):492-5 [1700886.001]
  • [Cites] J Laryngol Otol. 1995 Dec;109(12):1186-9 [8551153.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):791-9 [2764225.001]
  • [Cites] J Surg Oncol. 1986 Sep;33(1):69-71 [3762178.001]
  • [Cites] J Clin Pathol. 2000 Jul;53(7):554-7 [10961182.001]
  • [Cites] J Neurosurg. 1995 Nov;83(5):919-22 [7472566.001]
  • [Cites] Nebr Med J. 1996 Nov;81(11):359-62 [8979714.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1074-80 [11014574.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):790-5 [6249488.001]
  • [Cites] Riv Ital Stomatol. 1977 Nov;46:21-2 [278122.001]
  • [Cites] Cancer. 1963 Dec;16:1609-13 [14085275.001]
  • [Cites] Semin Diagn Pathol. 1994 Feb;11(1):15-25 [8202643.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Dec;52(12):1324-8 [7965339.001]
  • [Cites] Am J Dermatopathol. 1998 Feb;20(1):61-4 [9504672.001]
  • [Cites] Urology. 1992 Mar;39(3):271-3 [1546423.001]
  • [Cites] Am Surg. 1995 Mar;61(3):271-6 [7887545.001]
  • [Cites] J Pediatr Surg. 1979 Feb;14(1):91-4 [423075.001]
  • (PMID = 15942804.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


5. Miettinen M, Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med; 2006 Oct;130(10):1466-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
  • CONTEXT: Gastrointestinal stromal tumors (GISTs) are specific, generally Kit (CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors.
  • Five percent of GISTs occur in patients with neurofibromatosis type 1 syndrome (multiple small intestinal tumors) and in Carney triad (gastric epithelioid GISTs in young females).
  • Histologically GISTs vary from spindle cell tumors to epithelioid and pleomorphic tumors.
  • Most GISTs (95%) express Kit (CD117), CD34 (70%), and heavy caldesmon (80%), whereas 25% are positive for smooth muscle actin and less than 5% for desmin.
  • Tumor size and mitotic activity are best predictive prognostic features; small intestinal tumors behave more aggressively than gastric tumors with similar parameters.
  • Some Kit and PDGFRA mutations have a prognostic value.
  • [MeSH-major] Gastrointestinal Stromal Tumors / genetics. Gastrointestinal Stromal Tumors / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Incidence. Intestinal Neoplasms / pathology. Intestine, Small. Mutation. Prognosis. Proto-Oncogene Proteins c-kit / genetics. Receptor, Platelet-Derived Growth Factor alpha / genetics. Stomach Neoplasms / pathology. Syndrome


6. Okuda Y, Mori Y, Katoh Y, Iguchi M, Katoh M, Yamazaki D: [Case of small cell carcinoma of the urinary bladder effectively treated with adjuvant chemotherapy and radiotherapy following TUR]. Hinyokika Kiyo; 2009 May;55(5):267-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We suspected carcinoma in situ but two months after cystoscopy showed a non-papillary and sessile tumor with calcification.
  • We performed transurethral resection of the bladder tumor, muscle layer and adipose tissue.
  • Histopathological findings revealed small cell carcinoma of the bladder infiltrating the externaladipose tissue.
  • Follow up magnetic resonance imaging revealed disappearance of the bladder tumor.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Urinary Bladder Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507545.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R: Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med; 2005 Feb;46(2):253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In radiotherapy of head and neck cancer (HNC) and non-small cell lung cancer (NSCLC), hypoxia is known to be an important prognostic factor for long-term survival and local tumor control.
  • The PET tracer (18)F-fluoromisonidazole (FMISO) allows noninvasive assessment of tumor hypoxia.
  • This study analyzed whether FMISO PET could predict tumor recurrence after radiotherapy.
  • Standardized uptake values (SUVs) and ratios to reference tissues (mediastinum or muscle) were calculated.
  • RESULTS: For HNC, patients with local recurrence could be separated from disease-free patients by SUV 4 h after injection (all recurrences had an SUV > 2).
  • The tumor-to-muscle ratios (T/Mu) and tumor-to-mediastinum ratios (T/Me) at 4 h after injection correlated with the risk of relapse in both tumor entities: All patients with a T/Me greater than 2.0 (NSCLC, n = 5) or with a T/Mu greater than 1.6 (HNC, n = 5) presented with tumor recurrence, whereas only 3 of the remaining 11 patients experienced recurrence (27%).
  • Eighteen patients categorized by curve type could be followed up: In 5 of 6 patients with an accumulation curve, disease recurred locally within 1 y, compared with 5 of 8 patients with a delayed-washout curve and 0 of 4 with a rapid-washout curve.
  • CONCLUSION: Our results indicate that outcome after radiotherapy can be predicted on the basis of kinetic behavior of FMISO in tumor tissue.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Carcinoma, Non-Small-Cell Lung / radiotherapy. Head and Neck Neoplasms / radionuclide imaging. Head and Neck Neoplasms / radiotherapy. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / radiotherapy. Misonidazole / analogs & derivatives. Neoplasm Recurrence, Local / radionuclide imaging


8. Okarvi SM, Jammaz IA: Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer. Anticancer Res; 2009 Apr;29(4):1399-409
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
  • HER2/neu and MUC1-based synthetic peptides were prepared and evaluated in an effort to develop peptide-based radiopharmaceuticals derived from tumor-associated-antigens for the detection of breast cancer.
  • The relatively low expression of these antigens on normal tissues makes them attractive targets for tumor imaging.
  • Additionally, they exhibited a rapid internalization into tumor cells.
  • The peptides showed moderate tumor uptake (up to 2.2+/-0.98% ID/g) in nude mice carrying breast tumor xenografts.
  • The uptake in the tumor was always higher than in the blood and muscle.
  • A fast clearance from the blood and low accumulation (<6% ID/g) by the major organs was obtained in nude mice resulting in favorable tumor/blood and tumor/muscle ratios as early as 1 h after injection.
  • The combination of favorable in vitro and in vivo characteristics makes this new and interesting class of peptides potential candidates for the diagnosis of breast cancer in vivo.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Breast Neoplasms / radionuclide imaging. Mucin-1 / immunology. Peptide Fragments / chemical synthesis. Peptide Fragments / pharmacokinetics. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Receptor, ErbB-2 / immunology
  • [MeSH-minor] Animals. Drug Design. Female. Humans. In Vitro Techniques. Mice. Mice, Inbred BALB C. Mice, Nude. Organotechnetium Compounds / chemical synthesis. Organotechnetium Compounds / pharmacokinetics. Tissue Distribution. Tumor Cells, Cultured


9. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • p16 is a cyclin-dependent kinase-4 inhibitor that is expressed in a limited range of normal tissues and tumors.
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • In the vulva, p16 is positive in HPV-associated vulval intraepithelial neoplasia (VIN) but negative in VIN not associated with HPV.
  • Similarly, HPV-associated invasive squamous carcinomas are p16-positive, whereas the more common non-HPV-associated neoplasms are largely negative or focally positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


10. Røe K, Muren LP, Rørvik J, Olsen DR, Dahl O, Bakke A, Malinen E: Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Acta Oncol; 2008;47(7):1257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DCEMRI parameters derived from tumor and muscle contrast uptake curves were extracted and subjected to correlation analysis with tumor volume as well as clinical, pathological, histological and T2-weighted MR tumor stage.
  • For parameters showing a significant correlation with tumor stage, 3D malignancy maps were generated.
  • RESULTS: No significant relationships were found between tumor volume and extracted DCEMRI parameters.
  • The normalized area between tumor and muscle contrast uptake curves (nABC) evaluated from 0-180 seconds (nABC(180)) and 0-480 s (nABC(480)) correlated significantly with tumor stage (p=0.047 and p=0.035, respectively).
  • CONCLUSIONS: The nABC(180) and nABC(480) may provide added value in staging of bladder cancer.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Contrast Media. Humans. Image Enhancement. Middle Aged. Neoplasm Staging / methods. Radiotherapy / methods. Radiotherapy Dosage. Tumor Burden

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618299.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


11. Crossland H, Constantin-Teodosiu D, Greenhaff PL, Gardiner SM: Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle. J Physiol; 2010 Apr 15;588(Pt 8):1333-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle.
  • We recently provided evidence suggesting a role for cytokine-mediated inhibition of Akt/Forkhead box O 1 (FOXO1) signalling in the induction of muscle atrophy and impairment of muscle carbohydrate oxidation during lipopolysaccharide (LPS)-induced endotoxaemia in rats.
  • We hypothesized that a low-dose dexamethasone (Dex; anti-inflammatory agent) infusion during endotoxaemia would prevent the LPS-induced impairment of Akt/FOXO1 signalling, and therefore prevent the muscle atrophy and impairment of carbohydrate oxidation.
  • LPS infusion caused haemodynamic changes consistent with a hyperdynamic circulation and induced increases in muscle tumour necrosis factor-alpha (TNF-alpha; 10-fold, P < 0.001), interleukin-6 (IL-6; 14-fold, P < 0.001) and metallothionein-1A (MT-1A; 187-fold, P < 0.001) mRNA expression.
  • Dex co-administration abolished most of the haemodynamic effects of LPS and reduced the increase in muscle TNF-alpha, IL-6 and MT-1A by 51% (P < 0.01), 85% (P < 0.001) and 58% (P < 0.01), respectively.
  • Dex infusion during endotoxaemia also prevented the LPS-induced 40% reduction in the muscle protein:DNA ratio and decrease in Akt phosphorylation, and partially prevented the reduction in FOXO1 phosphorylation.
  • However, Dex did not prevent the LPS-mediated increase in muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MuRF1) mRNA expression, but did significantly reduce the LPS-mediated increase in cathepsin-L mRNA expression and enzyme activity by 43% (P < 0.001) and 53% (P < 0.05), respectively.
  • Furthermore, Dex suppressed LPS-induced pyruvate dehydrogenase kinase 4 (PDK4) mRNA upregulation by approximately 50% (P < 0.01), and prevented LPS-mediated muscle glycogen breakdown and lactate accumulation.
  • Thus, low-dose Dex infusion during endotoxaemia prevented muscle atrophy and the impairment of carbohydrate oxidation, potentially through suppression of cytokine-mediated Akt/FOXO inhibition, and blunting of cathepsin-L-mediated lysosomal protein breakdown.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Autophagy. 2008 Apr;4(3):378-80 [18227643.001]
  • [Cites] J Physiol. 2007 Aug 15;583(Pt 1):381-90 [17540700.001]
  • [Cites] J Physiol. 2008 Mar 15;586(6):1767-75 [18218678.001]
  • [Cites] Autophagy. 2008 May;4(4):524-6 [18367868.001]
  • [Cites] Arch Biochem Biophys. 2008 Jun 1;474(1):91-101 [18328801.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 May;110(1-2):125-9 [18436443.001]
  • [Cites] Br J Pharmacol. 2008 Aug;154(8):1600-10 [18500354.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1753-62 [18757479.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C986-93 [18701653.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E762-71 [18492780.001]
  • [Cites] J Physiol. 2008 Nov 15;586(Pt 22):5589-600 [18818241.001]
  • [Cites] J Physiol. 2009 Jan 15;587(Pt 1):219-30 [19001041.001]
  • [Cites] J Physiol. 2009 Jan 15;587(Pt 1):231-9 [19001043.001]
  • [Cites] J Physiol. 2009 Feb 15;587(Pt 4):713-9 [19218620.001]
  • [Cites] Biochem J. 2010 Apr 1;427(1):171-8 [20088826.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):47-55 [18035477.001]
  • [Cites] Toxicology. 2000 Nov 30;155(1-3):17-26 [11154793.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7):1303-10 [11445675.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7 Suppl):S117-20 [11445745.001]
  • [Cites] Biochem J. 2001 Nov 15;360(Pt 1):143-50 [11696001.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1704-8 [11679633.001]
  • [Cites] Br J Anaesth. 2003 Feb;90(2):221-32 [12538380.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):571-9 [12689661.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):365-71 [12820900.001]
  • [Cites] FASEB J. 2004 Jan;18(1):39-51 [14718385.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2004 May;7(3):265-9 [15075917.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):395-403 [15125842.001]
  • [Cites] Diabetes. 2004 Jul;53(7):1790-7 [15220203.001]
  • [Cites] Cell. 2004 Oct 15;119(2):285-98 [15479644.001]
  • [Cites] Scand J Clin Lab Invest. 1974 Apr;33(2):109-20 [4852173.001]
  • [Cites] Comput Biol Med. 1987;17(2):85-99 [3581810.001]
  • [Cites] N Engl J Med. 1987 Sep 10;317(11):653-8 [3306374.001]
  • [Cites] Circ Shock. 1989 May;28(1):59-68 [2731322.001]
  • [Cites] Metabolism. 1990 Oct;39(10):1096-107 [2215256.001]
  • [Cites] Am J Physiol. 1991 Mar;260(3 Pt 1):E430-5 [1900669.001]
  • [Cites] Clin Sci (Lond). 1991 Aug;81(2):249-56 [1716189.001]
  • [Cites] Am J Physiol. 1992 Apr;262(4 Pt 1):E427-33 [1566829.001]
  • [Cites] Mol Cell Biochem. 1993 Aug 11;125(1):11-8 [8264567.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1850-8 [7829521.001]
  • [Cites] Clin Investig. 1994 Oct;72(10):782-7 [7865982.001]
  • [Cites] Crit Care Med. 1995 Aug;23(8):1430-9 [7634816.001]
  • [Cites] Clin Sci (Lond). 1995 Oct;89(4):431-9 [7493444.001]
  • [Cites] J Clin Invest. 1996 Jan 15;97(2):339-48 [8567953.001]
  • [Cites] J Clin Invest. 1996 Apr 1;97(7):1610-7 [8601625.001]
  • [Cites] Crit Care Med. 1996 Apr;24(4):575-83 [8612406.001]
  • [Cites] Br J Pharmacol. 1996 May;118(1):141-9 [8733587.001]
  • [Cites] Am J Physiol. 1997 Mar;272(3 Pt 2):R849-56 [9087646.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):197-203 [9202072.001]
  • [Cites] Shock. 1998 Oct;10(4):298-306 [9788663.001]
  • [Cites] Br J Pharmacol. 1998 Dec;125(7):1543-50 [9884083.001]
  • [Cites] J Nutr. 1999 Jan;129(1S Suppl):227S-237S [9915905.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):202-4, 206 [10023525.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Crit Care Med. 2004 Nov;32(11 Suppl):S527-33 [15542960.001]
  • [Cites] J Appl Physiol (1985). 2005 Mar;98(3):911-7 [15542570.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Oct;37(10):2156-68 [16125115.001]
  • [Cites] Diabetes. 2005 Oct;54(10):2939-45 [16186396.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Diabetes. 2006 Aug;55(8):2311-7 [16873695.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4160-8 [16777975.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E501-12 [17003238.001]
  • [CommentIn] J Physiol. 2010 Apr 15;588(Pt 8):1193 [20395471.001]
  • (PMID = 20176631.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Glucocorticoids; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / Tumor Necrosis Factor-alpha; 147604-79-3 / Foxo1 protein, rat; 7S5I7G3JQL / Dexamethasone; EC 2.7.- / Protein Kinases; EC 2.7.1.- / pyruvate dehydrogenase kinase 4; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2872737
  •  go-up   go-down


12. Li YS, Davidson E, Reid CN, McHale AP: Optimising ultrasound-mediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: potential applications for gene therapy of cancer. Cancer Lett; 2009 Jan 8;273(1):62-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimising ultrasound-mediated gene transfer (sonoporation) in vitro and prolonged expression of a transgene in vivo: potential applications for gene therapy of cancer.
  • Using ultrasound-mediated transfection together with an episomal plasmid-based gene expression system, we demonstrate prolonged functional gene expression of luciferase in mouse hind leg muscle and in tumours in vivo.
  • [MeSH-major] Gene Transfer Techniques. Genetic Therapy. Neoplasms / drug therapy. Neoplasms / therapy. Transgenes


13. Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A: Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol; 2009 Jun;113(3):324-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.
  • OBJECTIVE: This retrospective study was designed to evaluate the clinicopathologic features and outcomes of a cohort of patients diagnosed with uterine smooth muscle tumor of uncertain malignant potential (STUMP) seen at a single institution.
  • Variables of interest included age at diagnosis, recurrence rate, and disease-free and overall survival.
  • The mean age at diagnosis was 43 years (range 25-75 years).
  • One of the three patients who had recurrent disease was found to have a leiomyosarcoma at the time of recurrence.
  • All three patients with recurrence were alive and disease-free at a mean follow-up time of 121 months.
  • [MeSH-major] Leiomyosarcoma / pathology. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342083.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA101642
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Cai W, Chen K, Li ZB, Gambhir SS, Chen X: Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med; 2007 Nov;48(11):1862-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature.
  • The development of a dual-function PET/near-infrared fluorescence (NIRF) probe can allow for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs.
  • PET/NIRF imaging, tissue homogenate fluorescence measurement, and immunofluorescence staining were performed with U87MG tumor-bearing mice to quantify the probe uptake in the tumor and major organs.
  • The U87MG tumor uptake of (64)Cu-labeled DOTA-QD was less than 1 percentage injected dose per gram (%ID/g), significantly lower than that of (64)Cu-labeled DOTA-QD-RGD (2.2 +/- 0.3 [mean +/- SD] and 4.0 +/- 1.0 %ID/g at 5 and 18 h after injection, respectively; n = 3).
  • Taking into account all measurements, the liver-, spleen-, and kidney-to-muscle ratios for (64)Cu-labeled DOTA-QD-RGD were about 100:1, 40:1, and 1:1, respectively.
  • On the basis of the PET results, the U87MG tumor-to-muscle ratios for DOTA-QD-RGD and DOTA-QD were about 4:1 and 1:1, respectively.
  • Excellent linear correlation was obtained between the results measured by in vivo PET imaging and those measured by ex vivo NIRF imaging and tissue homogenate fluorescence (r(2) = 0.93).
  • Histologic examination revealed that DOTA-QD-RGD targets primarily the tumor vasculature through an RGD-integrin alpha(v)beta(3) interaction, with little extravasation.
  • CONCLUSION: We quantitatively evaluated the tumor-targeting efficacy of a dual-function QD-based probe with PET and NIRF imaging.
  • This dual-function probe has significantly reduced potential toxicity and overcomes the tissue penetration limitation of optical imaging, allowing for quantitative targeted imaging in deep tissue.
  • [MeSH-major] Heterocyclic Compounds, 1-Ring / pharmacokinetics. Integrin alphaVbeta3 / metabolism. Neoplasms, Experimental / blood supply. Oligopeptides / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Chelating Agents. Copper Radioisotopes. Humans. Iodine Radioisotopes. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / radionuclide imaging. Peptides / pharmacokinetics. Positron-Emission Tomography. Quantum Dots. Spectroscopy, Near-Infrared. Tissue Distribution. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942800.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R01 CA119053; United States / NCI NIH HHS / CA / R21 CA102123; United States / NCI NIH HHS / CA / R21 CA121842; United States / NIBIB NIH HHS / EB / R21 EB001785; United States / NCI NIH HHS / CA / R24 CA93862; United States / NCI NIH HHS / CA / U54 CA119367
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Copper Radioisotopes; 0 / Heterocyclic Compounds, 1-Ring; 0 / Integrin alphaVbeta3; 0 / Iodine Radioisotopes; 0 / Oligopeptides; 0 / Peptides; 0 / Radiopharmaceuticals; 118337-11-4 / echistatin; 60239-18-1 / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; 99896-85-2 / arginyl-glycyl-aspartic acid
  •  go-up   go-down


15. Lakshmi VA, Chacko RT, Kurian S: Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):628-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumors: a 7-year experience from a tertiary care hospital.
  • BACKGROUND: Gastrointestinal stromal tumor (GIST), now the most common mesenchymal tumor of the gastrointestinal tract (GIT), has been frequently studied, especially with regard to its successful targeted therapy using imatinib mesylate.
  • AIM: Our aim was to describe the clinicopathological features of a large number of cases from a tertiary care hospital in India and report on the follow-up after treatment of some of the cases, comparing them with series described in the west.
  • RESULTS: Ninety-two cases of GIST were studied, which made up the largest group (52.8%) of mesenchymal tumors of the GIT, with smooth muscle tumors comprising 38.1%, the next large group.
  • A majority of them (70.4%) were of the high-risk malignant category, unlike most studies where high-risk tumors make up 30-45%.
  • Follow-up of 11 cases, the majority with high-risk tumor, treated with adjuvant imatinib for 6 months after surgical resection showed stable disease for periods from 2 to 5 years.
  • However, 11 cases treated with imatinib for longer than 6 months had a poorer outcome due to recurrent, metastatic, or inoperable disease.
  • CONCLUSION: In our study of a large number of GISTs, which were equally prevalent in the stomach and small intestine, the majority were of the high-risk malignant category and of pure spindle cell morphology.
  • Limited numbers had follow-up after imatinib therapy, which showed in one group treated for 6 months, after resection of high-risk GIST, stable disease for periods ranging from 2 to 5 years.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Intestinal Neoplasms / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045382.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


16. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW: Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med; 2006 Jun;47(6):989-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cu-Diacetyl-bis(N(4)-methylthiosemicarbazone) (Cu-ATSM) is a recently developed PET imaging agent for tumor hypoxia.
  • The tumor-to-muscle ratio (T/M ratio) and standardized uptake values (SUVs) were characterized for these 3 different types of tumors.
  • Spatial correlation analysis between (64)Cu-ATSM autoradiography and EF5 immunostained images varied between the 3 tumor types.
  • There was close correlation of (64)Cu-ATSM uptake and hypoxia in R3230Ac and 9L tumors but not in FSA tumors.
  • The same relationship was observed with 2 other hypoxia markers, pimonidazole and carbonic anhydrase IX, in FSA tumors.
  • These results indicate that some other (64)Cu-ATSM retention mechanisms, as opposed to hypoxia, are involved in this type of tumor.
  • CONCLUSION: To our knowledge, this study is the first comparison between (64)Cu-ATSM uptake and immunohistochemistry in these 3 tumors.
  • Although we have shown that (64)Cu-ATSM is a valid PET hypoxia marker in some tumor types, but not for all, this tumor type-dependent hypoxia selectivity of (64)Cu-ATSM challenges the use of (64)Cu-ATSM as a universal PET hypoxia marker.
  • [MeSH-major] Neoplasms / metabolism. Neoplasms / radionuclide imaging. Organometallic Compounds / pharmacokinetics. Oxygen / metabolism. Positron-Emission Tomography / methods. Thiosemicarbazones / pharmacokinetics
  • [MeSH-minor] Animals. Cell Hypoxia. Cell Line, Tumor. Copper Radioisotopes / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics. Rats. Rats, Inbred F344. Reproducibility of Results. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741309.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA40355; United States / NCI NIH HHS / CA / CA42745; United States / NCI NIH HHS / CA / R24 CA86307; United States / NCI NIH HHS / CA / R24 CA92656
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Copper Radioisotopes; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone); S88TT14065 / Oxygen
  •  go-up   go-down


17. Wyss MT, Honer M, Schubiger PA, Ametamey SM: NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging; 2006 Mar;33(3):311-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
  • PURPOSE: The purpose of this study was to assess the potential and utility of ultra-high-resolution hypoxia imaging in various murine tumour models using the established hypoxia PET tracer [(18)F]fluoromisonidazole ([(18)F]FMISO).
  • METHODS: [(18)F]FMISO PET imaging was performed with the dedicated small-animal PET scanner NanoPET (Oxford Positron Systems) and ten different human tumour xenografts in nude mice as well as B16 melanoma tumours in syngeneic Balb/c mice.
  • For comparison, [(18)F]fluorodeoxyglucose ([(18)F]FDG) PET scans were also performed in the mice bearing human tumour xenografts.
  • RESULTS: In 10 out of 11 experimental tumour models, [(18)F]FMISO PET imaging allowed clear-cut visualisation of the tumours.
  • In addition to average TMRR (tumour-to-muscle retention ratio including all voxels in a volume of interest (VOI)), the parameters TMRR(75%) and TMRR(5) (tumour-to-muscle retention ratio including voxels of 75% or more of the maximum radioactivity in a VOI and the five hottest pixels, respectively) also served as measures for quantifying the heterogeneous [(18)F]FMISO uptake in the tumours.
  • The variability observed in [(18)F]FMISO uptake was related neither to tumour size nor to the injected mass of the radiotracer.
  • The pattern of normoxic and hypoxic regions within the human tumour xenografts, however, correlated with glucose metabolism as revealed by comparison of [(18)F]FDG and [(18)F]FMISO images.
  • CONCLUSION: This study demonstrates the feasibility and utility of [(18)F]FMISO for imaging murine tumour models using NanoPET.
  • [MeSH-major] Misonidazole / analogs & derivatives. Nanotechnology / instrumentation. Neoplasms, Experimental / diagnostic imaging. Neoplasms, Experimental / metabolism. Oxygen / metabolism. Positron-Emission Tomography / instrumentation
  • [MeSH-minor] Animals. Cell Hypoxia. Equipment Design. Equipment Failure Analysis. Feasibility Studies. Female. Metabolic Clearance Rate. Mice. Mice, Inbred BALB C. Mice, Nude. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2323-35 [12114437.001]
  • [Cites] Strahlenther Onkol. 2004 Oct;180(10 ):616-22 [15480509.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):535-42 [11208848.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):717-8 [1524887.001]
  • [Cites] Med Inform (Lond). 1998 Jul-Sep;23 (3):207-14 [9785322.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):199-212 [1727119.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):253-60 [15695784.001]
  • [Cites] Head Neck. 1999 Mar;21(2):146-53 [10091983.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] J Nucl Med. 1993 Mar;34(3):411-3 [8441031.001]
  • [Cites] Radiat Res. 1987 Aug;111(2):292-304 [3628717.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2018-24 [10766193.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):1023-31 [8683295.001]
  • [Cites] Acta Oncol. 2002;41(3):304-12 [12195751.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1530-8 [15378285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):417-28 [8892467.001]
  • [Cites] J Surg Res. 2004 Aug;120(2):295-303 [15234226.001]
  • [Cites] Biochem Pharmacol. 1991 Nov 27;42(12 ):2387-95 [1764122.001]
  • [Cites] Eur J Nucl Med. 1999 Jul;26(7):750-7 [10398823.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1851-9 [15534054.001]
  • [Cites] Appl Radiat Isot. 1993 Aug;44(8):1085-91 [8358398.001]
  • [Cites] Acta radiol. 1960 Mar;53:233-56 [13808406.001]
  • [Cites] Br J Radiol. 1953 Dec;26(312):638-48 [13106296.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):117-28 [14523586.001]
  • [Cites] Breast Cancer Res. 2001;3(5):318-22 [11597321.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2232-42 [15150578.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):259-66 [12552344.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10 (7):2245-52 [15073099.001]
  • [Cites] Mol Imaging Biol. 2002 Jan;4(1):47-63 [14538048.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Phys Med Biol. 2004 May 21;49(10):2069-81 [15214542.001]
  • [Cites] J Nucl Med. 1992 Dec;33(12 ):2133-7 [1334136.001]
  • [Cites] Appl Radiat Isot. 2001 Jan;54(1):73-80 [11144255.001]
  • [Cites] Nucl Med Biol. 1996 Nov;23 (8):941-6 [9004282.001]
  • [Cites] Nucl Med Biol. 2000 Nov;27(8):693-700 [11150699.001]
  • [Cites] Eur Neuropsychopharmacol. 2002 Dec;12(6):545-55 [12468017.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):285-9 [9226314.001]
  • [Cites] Radiother Oncol. 2003 Jun;67(3):339-44 [12865184.001]
  • [Cites] Acta Oncol. 2000;39(5):629-37 [11093372.001]
  • [Cites] Strahlenther Onkol. 2004 May;180(5):297-305 [15127160.001]
  • [Cites] Radiology. 1995 Mar;194(3):795-800 [7862981.001]
  • [Cites] Nucl Med Biol. 2003 Apr;30(3):317-26 [12745023.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):379-87 [11786564.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):265-80 [7789400.001]
  • [Cites] Nuklearmedizin. 2003 Jun;42(3):86-9 [12802469.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):513-20 [14722675.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):581-6 [11173158.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Aug 1;45(1):171-80 [10477021.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):695-704 [12632200.001]
  • [Cites] Phys Med Biol. 1998 Apr;43(4):835-46 [9572508.001]
  • [Cites] Neoplasia. 2001 Jan-Feb;3(1):80-7 [11326319.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1947-54 [15520822.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1886-92 [14996753.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4509-15 [8813149.001]
  • [Cites] Semin Radiat Oncol. 2004 Jul;14 (3):241-8 [15254867.001]
  • (PMID = 16258762.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 082285VIDF / fluoromisonidazole; 8FE7LTN8XE / Misonidazole; S88TT14065 / Oxygen
  •  go-up   go-down


18. Giglio J, Patsis G, Pirmettis I, Papadopoulos M, Raptopoulou C, Pelecanou M, León E, González M, Cerecetto H, Rey A: Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. Eur J Med Chem; 2008 Apr;43(4):741-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synthesis of a ligand containing a nitrobenzyl group as bioreductive pharmacophore and the preparation of the corresponding technetium and rhenium complexes are presented. (99m)Tc labelling was performed in high yield (>90%) by ligand substitution using fac-[(99m)Tc(CO)(3)(H(2)O)(3)](+) as precursor.
  • Biodistribution in normal mice was characterized by fast blood and soft tissue depuration and combined excretion via the hepatobiliary and urinary systems.
  • Tumour uptake was low, probably due to low lipophilicity but tumour/muscle ratios were favourable as a consequence of high excretion.
  • [MeSH-minor] Animals. Cell Hypoxia. Crystallography, X-Ray. Diagnostic Imaging. In Vitro Techniques. Liver / metabolism. Lung / metabolism. Mice. Models, Molecular. Molecular Structure. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / etiology. Sarcoma, Experimental / metabolism. Spectrophotometry, Infrared. Structure-Activity Relationship. Tissue Distribution. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658668.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 7440-15-5 / Rhenium
  •  go-up   go-down


19. Kristek J, Marjanović K, Dmitrović B, Krajinović Z, Sakić K: Trichinella spiralis and breast carcinoma--a case report. Coll Antropol; 2005 Dec;29(2):775-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A local recurrence of the tumor was found on the chest wall six years after the surgery.
  • Tumor excision was performed.
  • Histological analysis pointed at a ductal invasive carcinoma with numerous parasites of Trichinella spiralis present within both the muscle and the tumor tissue.
  • The finding of parasites in the tumor tissue witnesses in favor of infestation, and the parasite morphology preserved in the tumor shows at the protective effects of the cysts, i.e. preventing parasite necrosis.
  • [MeSH-major] Breast Neoplasms / parasitology. Carcinoma, Ductal, Breast / parasitology. Neoplasm Recurrence, Local / parasitology. Trichinella spiralis. Trichinellosis / complications

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417199.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


20. O'Brien J, Loftus B, Barrett C, Torreggiani W: Leiomyoma of the testis: a rare testicular mass. J Clin Ultrasound; 2008 May;36(4):240-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the sonographic appearance of a testicular leiomyoma, which is a rare smooth muscle tumor of the testis.
  • The patient presented with a painless testicular mass that was confirmed as an intratesticular tumor on sonographic examination.
  • [MeSH-major] Leiomyoma / ultrasonography. Testicular Neoplasms / ultrasonography. Ultrasonography, Doppler, Color
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. J Clin Ultrasound, 2008.
  • (PMID = 18286504.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Wang L, Mazaheri Y, Zhang J, Ishill NM, Kuroiwa K, Hricak H: Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. Radiology; 2008 Jan;246(1):168-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SI of prostate tumors, nontumor prostatic tissue, and internal obturator muscles was measured on uncorrected and corrected T2-weighted MR images.
  • Gleason grade correlated significantly with tumor-muscle SI ratio for PZ tumors on corrected and uncorrected images (P = .006 and <.001, respectively).
  • Higher Gleason grades were associated with lower tumor-muscle SI ratios.
  • Nontumor-muscle SI ratios did not correlate with patients' Gleason grades.
  • Tumor-muscle SI ratios were lower in TZ than in PZ tumors (P < .001).
  • CONCLUSION: Higher Gleason grades were associated with lower tumor-muscle SI ratios on T2-weighted MR images.
  • [MeSH-major] Magnetic Resonance Imaging. Prostatectomy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2007
  • (PMID = 18024440.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA76423
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


22. Perez EA, Gutierrez JC, Jin X, Lee DJ, Rocha-Lima C, Livingstone AS, Franceschi D, Koniaris LG: Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination. J Gastrointest Surg; 2007 Jan;11(1):114-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination.
  • OBJECTIVE: We sought to determine patient outcomes after different surgical approaches for gastrointestinal sarcomas, including gastrointestinal stromal tumors (GIST), utilizing a large prospective cancer registry.
  • RESULTS: Overall, 1873 gastrointestinal mesenchymal tumors were identified in the SEER data set, with 82% GIST and 18% smooth muscle neoplasms.
  • Median survival rates for localized, regionally advanced, and metastatic disease were 97, 35, and 18 months, respectively, after CR, and in all cases significantly improved relative to patients not undergoing resection.
  • CONCLUSIONS: The outcomes after surgical therapy for gastrointestinal sarcomas, including GIST, support the operative goal of a complete resection.
  • [MeSH-major] Gastrointestinal Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Sarcoma / surgery

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Surgery. 2003 Oct;134(4):656-65; discussion 665-6 [14605627.001]
  • [Cites] J Am Coll Surg. 2006 Apr;202(4):623-9 [16571433.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] J Gastrointest Surg. 2005 May-Jun;9(5):718-25 [15862270.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] J Gastroenterol. 2000;35 Suppl 12:75-9 [10779223.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1493-9 [11984533.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3211-20 [10986053.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):737-8; author reply 738-9 [12163398.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2735-43 [15837988.001]
  • [Cites] Ann Surg Oncol. 2001 May;8(4):290-9 [11352301.001]
  • (PMID = 17390197.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Berretta R, Rolla M, Merisio C, Giordano G, Nardelli GB: Uterine smooth muscle tumor of uncertain malignant potential: a three-case report. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumor of uncertain malignant potential: a three-case report.
  • Based on the degree of cytologic atypia, mitotic activity, and other features, uterine smooth muscle tumors have historically been grouped into two classes: benign leiomyomas and malignant leiomyosarcomas.
  • However, this separation holds true more in principle than in practice because the tumor's biological potential may not always be determined with certainty, complicating diagnosis, and therapy.
  • We report three cases of patients with uterine smooth muscle tumors of uncertain malignant potential.
  • Uterine smooth muscle tumors of uncertain malignant potential may have an unpredictable clinical course and may metastasize to seemingly low-grade neoplasms in distant sites even after several years and even in the absence of important negative prognostic predictors, such as coagulative tumor cell necrosis.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uncertainty. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / secondary. Middle Aged

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986240.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Pisano R, Breda M, Grassi S, James CA: Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues. J Pharm Biomed Anal; 2005 Jul 15;38(4):738-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After addition of internal standard (IS) (5-Chlorouracil (5-CU)), plasma proteins were precipitated with acetonitrile, and tissue samples homogenised with a micro-dismembrator.
  • The lower limits of quantitation in plasma and tissues were about 5 ng/ml and 10 ng/g, respectively, using 25 microl of plasma and 50mg of tissue.
  • The suitability and robustness of the method for in vivo samples were confirmed by analysis of mouse plasma, muscle and tumour from animals dosed with 5-FU.
  • [MeSH-minor] Animals. Calibration. Chemistry, Physical. Chromatography, Liquid. Mass Spectrometry. Mice. Physicochemical Phenomena. Reference Standards. Tissue Distribution. Uracil / analogs & derivatives. Uracil / analysis. Uracil / blood. Uracil / pharmacokinetics

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967302.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 56HH86ZVCT / Uracil; 7LQ4V03RNY / 5-chlorouracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Satpati D, Korde A, Kothari K, Sarma HD, Venkatesh M, Banerjee S: Preparation and in-vivo evaluation of (188)Re(CO)(3)-colchicine complex for use as tumor-targeting agent. Cancer Biother Radiopharm; 2008 Dec;23(6):741-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation and in-vivo evaluation of (188)Re(CO)(3)-colchicine complex for use as tumor-targeting agent.
  • Biodistribution studies were carried out in the murine fibrosarcoma tumor model.
  • Tumor uptake of 1.7 +/- 0.03 percent injected dose per g (%ID/g) was observed at 3 hours postinjection (h.p.i.
  • Tumor-blood and tumor-muscle ratios were 0.14 and 1 at 1 h.p.i. that increased to 0.95 and 4 at 24 h.p.i., respectively.
  • Retention of the complex in tumor for more than one half-life of (188)Re(t(1/2) = 17 hours) indicates its potentiality for tumor therapy.
  • [MeSH-minor] Animals. Half-Life. Mice. Tissue Distribution

  • Hazardous Substances Data Bank. COLCHICINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111049.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 188Re(CO)3-colchicine iminodiacetic acid; 0 / Coordination Complexes; 0 / Radioisotopes; SML2Y3J35T / Colchicine
  •  go-up   go-down


26. Tsuchiya K, Minami I, Tateno T, Izumiyama H, Doi M, Nemoto T, Mae S, Kasuga T, Osamura RY, Oki Y, Hirata Y: Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays. Endocr J; 2005 Dec;52(6):743-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 49-year-old male was found to have a large gastric tumor, with muscle wasting, hypertension, diabetes and hypokalemia caused by hypercortisolemia.
  • Pathological examination of the gastric tumor was consistent with the diagnosis of malignant carcinoid.
  • Immunohistochemical study revealed that immunoreactivity of proopiomelanocortin (POMC) was positive within the tumor cells, whereas those of ACTH and prohormone convertase 1/3 were negative.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Adrenocorticotropic Hormone / blood. Carcinoid Tumor / complications. Immunoradiometric Assay / methods. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoid Syndrome.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410667.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


27. Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG: Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res; 2005 Jun 1;11(11):4022-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is overexpressed in prostate cancer, including hormone-refractory and metastatic disease.
  • Radiopharmaceutical binding selectivity and tumor uptake were also evaluated in vivo using dedicated small animal positron emission tomography, single photon emission computed tomography, and gamma scintigraphic imaging devices.
  • RESULTS: At 30 minutes postinjection, [(11)C]DCMC and [(125)I]DCIT showed tumor/muscle ratios of 10.8 and 4.7, respectively, with clear delineation of LNCaP-derived tumors on imaging.
  • MCF-7- and PC-3-derived tumors showed significantly less uptake of [(11)C]DCMC or [(125)I]DCIT.
  • [MeSH-major] Antigens, Surface / metabolism. Glutamate Carboxypeptidase II / metabolism. Positron-Emission Tomography / methods. Prostatic Neoplasms / radionuclide imaging
  • [MeSH-minor] Animals. Binding, Competitive. Carbon Radioisotopes. Cell Line, Tumor. Female. Humans. Iodine Radioisotopes. Ligands. Male. Mice. Mice, SCID. Neoplasm Transplantation. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / metabolism. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15930336.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101069; United States / NCI NIH HHS / CA / CA103175; United States / NCI NIH HHS / CA / CA82871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carbon Radioisotopes; 0 / Iodine Radioisotopes; 0 / Ligands; 0 / Radiopharmaceuticals; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


28. Iarŭmov N, Velev G, Todorov G, Lukanova Ts, Angelov K, Gribnev P, Sokolov M, Toshev S: [Gastrointestinal stromal tumors (GIST) - clinical experience and current therapeutical aspects]. Khirurgiia (Sofiia); 2007;(4):27-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumors (GIST) - clinical experience and current therapeutical aspects].
  • Gastrointestinal stromal tumors (GIST) are specific, generally Kit (CD117) - positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously considered gastrointestinal smooth muscle tumors.
  • Diagnosis is based on histological and immunohistochemical examination, and these rare tumors are characterized by c-kit (CD117) staining.
  • We present an analysis of clinical presentation and course, surgical management and pathological features of 11 patients with gastrointestinal stromal tumors treated in our institution from 2002 to 2007.
  • 2 patients with malignant retroperitoneal GIST had disease progression/recurrence and died.
  • 9 patients are disease free on the 3-d year of the follow-up.
  • Our results confirm that in stromal tumors complete surgical resection remains the mainstay of treatment in localized gastrointestinal stromal tumors.
  • Complete removal of the tumor is often curative in localized gastrointestinal stromal tumors and is always recommended.
  • Clinically, their behavior is difficult to predict, and mitotic count and tumor size seem to be the most effective prognostic factors.
  • It is conceivable that treatment and prognosis of metastatic and non - resectable gastrointestinal stromal tumors, as well as the adjuvant treatment of high-risk, radically excised gastrointestinal stromal tumors will be strongly impacted by the c-kit target therapy.
  • [MeSH-major] Gastrointestinal Stromal Tumors
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Benzamides. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Imatinib Mesylate. Male. Middle Aged. Mutation. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use. Receptor, Platelet-Derived Growth Factor alpha / genetics

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443532.001).
  • [ISSN] 0450-2167
  • [Journal-full-title] Khirurgii︠a︡
  • [ISO-abbreviation] Khirurgiia (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  •  go-up   go-down


29. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, Dingemans AM, Lalisang R, Brans B, Windhorst B, van Dongen GA, Kolb H, Zhang J, De Ruysscher D, Lambin P: PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging; 2010 Aug;37(9):1663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers.
  • A study design with two dose steps was used in which a single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [(18)F]HX4 was injected.
  • PET/CT images of the largest tumour site were acquired 30, 60 and 120 min after injection.
  • The median tumour to muscle ratio 120 min after injection was 1.40 (range 0.63-1.98).
  • [MeSH-minor] Aged. Cell Hypoxia. Dose-Response Relationship, Drug. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasms / diagnostic imaging. Neoplasms / pathology. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1392-8 [17512190.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):106-13 [15632040.001]
  • [Cites] Radiat Res. 1987 Aug;111(2):292-304 [3628717.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1544-9 [18509637.001]
  • [Cites] Radiother Oncol. 2008 Apr;87(1):142-6 [18207269.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):240-57 [11803141.001]
  • [Cites] Eur J Nucl Med. 1995 Mar;22(3):265-80 [7789400.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:129S-48S [18523070.001]
  • [Cites] J Cell Biochem. 2009 Aug 15;107(6):1053-62 [19479945.001]
  • [Cites] Phys Med Biol. 2005 May 21;50(10 ):2209-24 [15876662.001]
  • (PMID = 20369236.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol; 0 / Nitroimidazoles; 0 / Triazoles
  •  go-up   go-down


30. Dietz KN, Miller PJ, Hollenbach AD: Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation. Biochemistry; 2009 Dec 15;48(49):11786-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation of serine 205 by the protein kinase CK2 persists on Pax3-FOXO1, but not Pax3, throughout early myogenic differentiation.
  • The myogenic transcription factor Pax3 plays an essential role in early skeletal muscle development and is a key component in alveolar rhabdomyosarcoma (ARMS), a childhood solid muscle tumor.
  • In addition, it is not known whether Pax3-FOXO1 is phosphorylated at this site or how the phosphorylation of the fusion protein changes during early myogenic differentiation.
  • Furthermore, we demonstrate that, in contrast to wild-type Pax3, phosphorylation at Ser205 persists on Pax3-FOXO1 throughout early myogenic differentiation.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4501-7 [3607778.001]
  • [Cites] Annu Rev Biochem. 1987;56:567-613 [2956925.001]
  • [Cites] Cell. 1987 Sep 11;50(6):823-9 [3113737.001]
  • [Cites] Biochem J. 1989 Sep 1;262(2):469-73 [2803263.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Sep;31(9):941-9 [10533285.001]
  • [Cites] EMBO J. 2000 Sep 15;19(18):4997-5006 [10990463.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4119-27 [11051265.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3247-57 [11423974.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7174-83 [11742994.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):41-7 [11988074.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Lett. 2002 Jul 8;181(1):87-93 [12430183.001]
  • [Cites] J Antimicrob Chemother. 2002 Dec;50(6):779-92 [12460995.001]
  • [Cites] Biochem J. 2003 Jan 1;369(Pt 1):1-15 [12396231.001]
  • [Cites] FASEB J. 2003 Mar;17(3):349-68 [12631575.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43346-56 [12904290.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6650-60 [15475455.001]
  • [Cites] J Biol Chem. 1980 Sep 10;255(17):8038-41 [6447694.001]
  • [Cites] Eur J Biochem. 1990 Jan 12;187(1):89-94 [2105215.001]
  • [Cites] Eur J Biochem. 1990 Apr 30;189(2):251-7 [2159876.001]
  • [Cites] Biochim Biophys Acta. 1990 Sep 24;1054(3):267-84 [2207178.001]
  • [Cites] Development. 1994 Mar;120(3):603-12 [8162858.001]
  • [Cites] Science. 1995 Feb 10;267(5199):894-7 [7846532.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] FASEB J. 1995 Mar;9(5):313-23 [7896000.001]
  • [Cites] J Biol Chem. 1995 May 19;270(20):11719-22 [7744814.001]
  • [Cites] Cancer Lett. 1996 Mar 19;101(1):31-5 [8625279.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1604-13 [8657135.001]
  • [Cites] J Biol Chem. 1996 Jul 19;271(29):17199-204 [8663403.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Biol Chem. 1997 Dec;378(12):1445-56 [9461343.001]
  • [Cites] Cardiovasc Res. 1997 Nov;36(2):163-73 [9463628.001]
  • [Cites] FEBS Lett. 1998 Jan 23;422(1):118-22 [9475182.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4118-30 [9632796.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5009-13 [9823299.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):594-601 [9858583.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):1093-102 [10023686.001]
  • [Cites] EMBO J. 1999 Jul 1;18(13):3702-11 [10393185.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):884-7 [15729346.001]
  • [Cites] Anticancer Drugs. 2005 Nov;16(10):1037-43 [16222144.001]
  • [Cites] Mol Cell Biochem. 2005 Jun;274(1-2):63-7 [16342409.001]
  • [Cites] Mol Cell Biochem. 2005 Jun;274(1-2):69-76 [16335530.001]
  • [Cites] Mol Cell Biochem. 2005 Jun;274(1-2):77-84 [16342410.001]
  • [Cites] Biochim Biophys Acta. 2007 Oct;1770(10):1450-8 [17698292.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:645-73 [17506689.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2004-14 [17922034.001]
  • [Cites] Cell Stem Cell. 2008 Jan 10;2(1):50-9 [18371421.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3767-76 [18483260.001]
  • [Cites] Protein Sci. 2008 Nov;17(11):1979-86 [18708529.001]
  • (PMID = 19904978.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA138656-01A1; United States / NCI NIH HHS / CA / R01 CA138656-01A1; United States / NCI NIH HHS / CA / 1R01CA138656; United States / NCRR NIH HHS / RR / P20 RR020152; United States / NCRR NIH HHS / RR / RR020152-066702; United States / NCRR NIH HHS / RR / 1P20RR020152; United States / NCI NIH HHS / CA / R01 CA138656; United States / NCRR NIH HHS / RR / P20 RR020152-066702
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FOXO1A fusion protein, human; 0 / Paired Box Transcription Factors; 138016-91-8 / Pax3 protein, mouse; 452VLY9402 / Serine; EC 2.7.11.1 / Casein Kinase II
  • [Other-IDs] NLM/ NIHMS159458; NLM/ PMC2790557
  •  go-up   go-down


31. Agaimy A, Wünsch PH: True smooth muscle neoplasms of the gastrointestinal tract: morphological spectrum and classification in a series of 85 cases from a single institute. Langenbecks Arch Surg; 2007 Jan;392(1):75-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] True smooth muscle neoplasms of the gastrointestinal tract: morphological spectrum and classification in a series of 85 cases from a single institute.
  • BACKGROUND AND AIM: True smooth-muscle neoplasms of the GI tract have been only rarely studied in the KIT era.
  • Their incidence among other GI mesenchymal tumours and their clinicopathological spectrum have not been sufficiently analysed.
  • RESULTS: Among 262 lesions, there were 142 GISTs (54%) and 85 true smooth muscle neoplasms (32%).
  • Smooth muscle neoplasms comprised 72 polypoid leiomyomas (78%, 5 oesophageal and 67 colorectal), 10 intramural leiomyomas (11%, 5 oesophageal, 4 gastric and one ileal), two intramural leiomyosarcomas in the sigmoid colon and ileum (2%) and one polypoid leiomyosarcoma involving the stomach, descending colon and the retroperitoneum concurrently.
  • CONCLUSION: Smooth muscle neoplasms are the second most common mesenchymal neoplasms in the GI tract after GISTs.
  • They may arise either from the muscularis mucosae or proper muscle layer forming polypoid and intramural lesions, respectively.
  • Intramural leiomyosarcomas are rare high-grade sarcomas that commonly have infiltrated into the surrounding tissue or metastasised by the time of diagnosis.
  • [MeSH-major] Gastrointestinal Neoplasms / classification. Gastrointestinal Stromal Tumors / pathology. Leiomyoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1975 Oct;20(4):405-17 [1180595.001]
  • [Cites] Histopathology. 2006 Jan;48(1):97-105 [16359541.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):14-24 [11756765.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):570-2 [2297646.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):52-68 [15613856.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:400-9 [13917556.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):142-50 [15232741.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1355-63 [11684951.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):950-6 [11598163.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):211-22 [10680889.001]
  • [Cites] Hum Pathol. 1998 May;29(5):476-81 [9596271.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Natl Med Assoc. 1992 Jul;84(7):629-31 [1629928.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):756-62 [10463476.001]
  • [Cites] Scand J Gastroenterol. 2005 Dec;40(12):1502-6 [16293565.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):288-94 [16308708.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1627-33 [12459630.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • (PMID = 17021790.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Nimmagadda S, Pullambhatla M, Pomper MG: Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med; 2009 Jul;50(7):1124-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.
  • CXCR4-CXCL12 interactions are critical for tumor development, growth, and metastasis.
  • Compared with normal tissue, neoplastic tissue (including metastases) expresses high levels of CXCR4.
  • Here we report the results of SPECT/CT of CXCR4 expression levels in experimental brain tumors using (125)I-labeled anti-CXCR4 monoclonal antibodies (mAbs).
  • Surface CXCR4 expression levels on U87 tumor-derived cells were analyzed by flow cytometry.
  • RESULTS: Biodistribution and imaging studies showed a specific accumulation of (125)I-12G5 in U87 tumors, with tumor-to-muscle uptake ratios reaching 15 +/- 3 at 48 h after injection.
  • The tumor-to-tumor uptake ratio for (125)I-12G5 and (125)I-IgG(2A) was 2.5 at 48 h after injection.
  • Flow cytometry analysis of tumor-derived cells showed a 2- to 7-fold increase in CXCR4 expression relative to inoculums, accounting for the high mAb uptake observed in the tumors.
  • CONCLUSION: Our data demonstrate the feasibility of imaging CXCR4 expression in experimental brain tumors.
  • The elevated CXCR4 levels observed may have been, in part, due to the hypoxic tumor microenvironment.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 1997 Feb;71(2):1692-6 [8995702.001]
  • [Cites] Cancer Res. 1992 Feb 1;52(3):637-42 [1732052.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2368-72 [10452968.001]
  • [Cites] J Virol. 2005 Feb;79(3):1930-3 [15650218.001]
  • [Cites] Breast Cancer Res. 2005;7(4):153-62 [15987467.001]
  • [Cites] Breast Cancer Res. 2005;7(5):215-9 [16168141.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1784-92 [16251534.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1292-8 [16489086.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2801-6 [16407848.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2276-82 [16710024.001]
  • [Cites] Nucl Med Biol. 2006 May;33(4):489-94 [16720240.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2793-9 [16682724.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jun;97(3):275-83 [16344916.001]
  • [Cites] Lab Invest. 2006 Dec;86(12):1221-32 [17075581.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6765-71 [17121897.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47 [17333178.001]
  • [Cites] Neurosurgery. 2007 Sep;61(3):570-8; discussion 578-9 [17881971.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):281-5 [17763975.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):7975-80 [19088012.001]
  • [Cites] J Nucl Med. 2009 Jan;50(1):2-5 [19091888.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):102-11 [10656438.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] J Virol. 2001 Oct;75(19):8957-67 [11533159.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):462-73 [12761880.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21631-8 [12690099.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1957-71 [12796357.001]
  • [Cites] J Neurooncol. 2003 Jul;63(3):247-56 [12892230.001]
  • [Cites] Breast Cancer Res. 2003;5(5):R144-50 [12927045.001]
  • [Cites] J Exp Med. 2003 Nov 3;198(9):1391-402 [14597738.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Radiology. 1988 Oct;169(1):45-8 [3262228.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2807-13 [2469537.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):840s-845s [2297731.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):846s-851s [2297732.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3 Suppl):852s-856s [2297733.001]
  • [Cites] J Surg Oncol. 1998 Oct;69(2):99-104 [9808513.001]
  • (PMID = 19525448.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA092871-08; United States / NCI NIH HHS / CA / U24 CA092871; United States / NCI NIH HHS / CA / U24 CA092871-08; United States / NCI NIH HHS / CA / U24 CA92871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, CXCR4
  • [Other-IDs] NLM/ NIHMS281743; NLM/ PMC3075860
  •  go-up   go-down


33. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA: The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis; 2006 May;186(1):38-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGF receptor mediated processes have been well characterised within epithelial, smooth muscle and tumour cell lines in vitro, and the EGF receptor has been identified immunocytochemically on intimal smooth muscle cells within atherosclerotic plaques.


34. Lee CH, Ali R, Gilks CB: Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract. Surg Pathol Clin; 2009 Dec;2(4):823-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract.
  • Mesenchymal tumors of the female genital tract are a heterogeneous group of neoplasms that can be classified based on cellular differentiation into 3 main groups: smooth muscle tumors, endometrial stromal tumors, and other differentiated and undifferentiated tumors.
  • Genomic analysis techniques have revealed important genetic aberrations such as the t(7;17) translocation, resulting in JAZF1-JJAZ1 gene fusion, characteristic of endometrial stromal tumors.
  • These analyses have demonstrated genetic complexity and heterogeneity in many mesenchymal tumor types.
  • This article focuses on current understanding of the molecular genetics of mesenchymal tumors of the female genital tract, with emphasis on diagnostic and prognostic molecular features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 26838781.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; HMGA2 / Leiomyoma / Leiomyosarcoma / Low-grade endometrial stromal sarcoma / Undifferentiated endometrial sarcoma
  •  go-up   go-down


35. Kim K, Velez I, Kaltman SI, Lopez E, Stern D: Odontogenic carcinoma differentiation into rhabdomyosarcoma: report of a rare case. Quintessence Int; 2009 Nov-Dec;40(10):837-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Odontogenic carcinoma differentiation into rhabdomyosarcoma: report of a rare case.
  • To the authors' knowledge, this is the first reported case of an odontogenic carcinoma with documented skeletal muscle differentiation (rhabdomyosarcoma).
  • The histology and clinical features of this aggressive odontogenic neoplasm are described.
  • Within the English-language literature, only 2 cases are reported of an odontogenic tumor with muscle differentiation: a benign odontogenic tumor (ameloblastoma) with differentiation into a rhabdomyosarcoma and an odontogenic sarcoma with smooth-muscle differentiation.
  • The general practitioner should be aware that odontogenic lesions may be malignant, even though this is extremely rare, and all tissue removed from the oral cavity should be submitted for biopsy.
  • [MeSH-major] Gingival Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Odontogenic Tumors / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Maxillary Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898715.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Gangwar R, Ahirwar D, Mandhani A, Mittal RD: Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population? Mutat Res; 2009 Nov-Dec;680(1-2):56-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a recessive model, the OGG1 GG genotype showed an increased risk of TaG(2,3) + T1G(1-3) tumors.
  • XRCC7 also showed increased association with TaG(2,3) + T1G(1-3) tumors and muscle invasive tumors (OR, 3.16; p, 0.001 and OR, 4.24; p, 0.001, respectively).
  • Multiple Cox regression analysis in non-muscle invasive bladder tumor (NMIBT) patients demonstrated an association of the OGG1 GG polymorphism with a high risk of recurrence in patients on cystoscopic surveillance (HR, 4.04; p, 0.013).
  • CONCLUSION: Our data suggest association of a variant (GG) genotype of OGG1 with increased UBC susceptibility and a high risk of tumor recurrence in NMIBT patients on cystoscopic surveillance.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Glycosylases / genetics. DNA-Activated Protein Kinase / genetics. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Nuclear Proteins / genetics. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815090.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / X-ray repair cross complementing protein 3; EC 2.7.11.1 / DNA-Activated Protein Kinase; EC 2.7.11.1 / PRKDC protein, human; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human
  •  go-up   go-down


37. Kelesidis T: Smooth muscle tumour of the right groin: description of a unique case. Ir J Med Sci; 2010 Dec;179(4):603-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle tumour of the right groin: description of a unique case.
  • INTRODUCTION: A deep soft tissue smooth muscle tumour is a rare entity with few cases described in the literature.
  • MATERIALS AND METHODS: Herein, we report a case of a smooth muscle tumour of the right inguinal area which presented as a painful mass.
  • This case is unique because of the anatomic location of the tumour, which has not been reported before, and the clinical presentation of this tumour mimicked a hernia.
  • CONCLUSION: Smooth muscle tumours in the inguinal area are an exceptionally rare occurrence, but clinicians should always consider less routine causes for a painful inguinal mass.
  • [MeSH-major] Inguinal Canal / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Female. Humans. Immunohistochemistry. Prognosis. Smooth Muscle Tumor / drug therapy. Smooth Muscle Tumor / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1134-42 [11688572.001]
  • [Cites] Ann Diagn Pathol. 2003 Feb;7(1):60-6 [12616476.001]
  • [Cites] Am J Perinatol. 1992 May;9(3):185-9 [1374254.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):897-901 [9669352.001]
  • (PMID = 18825475.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


38. Liu D, Overbey D, Watkinson L, Giblin MF: Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem; 2009 May 20;20(5):888-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor uptake at this time was 0.53 +/- 0.11% ID/g, resulting in tumor/blood and tumor/muscle ratios of 4.2 and 9.4, respectively.
  • Uptake in tumor was significantly higher than that obtained using a scrambled control peptide that showed no specific binding to uPAR (p < 0.05).
  • In vitro and ex vivo results both suggested that the magnitude of tumor-specific binding was reduced in this model by endogenous expression of uPA.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioconjug Chem. 2007 Nov-Dec;18(6):1701-4 [17915958.001]
  • [Cites] Clin Exp Metastasis. 1996 May;14(3):297-307 [8674284.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64 [17891393.001]
  • [Cites] Pancreas. 2008 Mar;36(2):160-7 [18376307.001]
  • [Cites] Biochemistry. 2001 Oct 9;40(40):12157-68 [11580291.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2519-26 [11489835.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4758-66 [18676745.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):619-26 [12547719.001]
  • [Cites] J Nucl Med. 2003 May;44(5):823-31 [12732685.001]
  • [Cites] Recent Results Cancer Res. 2003;162:3-14 [12790317.001]
  • [Cites] Curr Pharm Des. 2003;9(19):1499-528 [12871065.001]
  • [Cites] Curr Pharm Des. 2003;9(19):1529-43 [12871066.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1545-55 [14977859.001]
  • [Cites] Chem Biol. 2004 Jan;11(1):99-106 [15112999.001]
  • [Cites] Bioconjug Chem. 2004 Jul-Aug;15(4):872-80 [15264876.001]
  • [Cites] Curr Pharm Des. 2004;10(19):2359-76 [15279614.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1381-9 [15299065.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939-43 [2991901.001]
  • [Cites] J Biol Chem. 1987 Apr 5;262(10):4437-40 [3031025.001]
  • [Cites] Biochemistry. 1994 Apr 26;33(16):4847-64 [8161544.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):7129-33 [8041758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12814-8 [9788997.001]
  • [Cites] Int J Oncol. 2005 Jan;26(1):113-9 [15586231.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):779-86 [15841327.001]
  • [Cites] EMBO J. 2005 May 4;24(9):1655-63 [15861141.001]
  • [Cites] J Nucl Med. 2005 Sep;46(9):1561-9 [16157541.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1707-18 [16204722.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Science. 2006 Feb 3;311(5761):656-9 [16456079.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1026-35 [16435385.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7957-67 [16912170.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):636-43 [10676647.001]
  • (PMID = 19354275.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103130-01; United States / NCI NIH HHS / CA / P50 CA103130; United States / NCI NIH HHS / CA / 1 P50 CA103130-01; United States / NCI NIH HHS / CA / P50 CA103130-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Peptide Fragments; 0 / Receptors, Urokinase Plasminogen Activator; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS109236; NLM/ PMC2885567
  •  go-up   go-down


39. Diepart C, Jordan BF, Gallez B: A New EPR oximetry protocol to estimate the tissue oxygen consumption in vivo. Radiat Res; 2009 Aug;172(2):220-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A New EPR oximetry protocol to estimate the tissue oxygen consumption in vivo.
  • Abstract The oxygen consumption rate in tumors affects tumor oxygenation and response to therapies.
  • A new EPR method was developed to measure tissue oxygen consumption non-invasively.
  • (1) basal value during air breathing;.
  • (2) saturation of tissue with oxygen by carbogen breathing;.
  • The assumption was that the kinetics of the return to the basal value after oxygen saturation would be governed mainly by tissue oxygen consumption.
  • This challenge was applied in hyperthyroid mice (generated by chronic treatment with l-thyroxine) and control mice because hyperthyroidism is known to dramatically affect the oxygen consumption rate of tumor and muscle cells.
  • Muscle and tumor cells from the hyperthyroid mice consumed oxygen faster than muscle and tumor cells from the control mice, which is consistent with the results of in vitro studies.
  • Tumor perfusion was not affected by the treatment with l-thyroxine.
  • [MeSH-major] Algorithms. Electron Spin Resonance Spectroscopy / methods. Liver Neoplasms / metabolism. Oximetry / methods. Oxygen / analysis. Oxygen / metabolism. Oxygen Consumption
  • [MeSH-minor] Animals. Mice. Reproducibility of Results. Sensitivity and Specificity. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630526.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


40. Staples BJ, Pitt WG, Roeder BL, Husseini GA, Rajeev D, Schaalje GB: Distribution of doxorubicin in rats undergoing ultrasonic drug delivery. J Pharm Sci; 2010 Jul;99(7):3122-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, US was used to deliver doxorubicin (Dox) sequestered in micelles in an in vivo rat model with bilateral leg tumors.
  • One of two frequencies with identical mechanical index and intensity was delivered for 15 min to one tumor immediately after systemic injection of micellar Dox.
  • Pharmacokinetics in myocardium, liver, skeletal muscle, and tumors were measured for 1 week.
  • When applied in combination with micellar Dox, the ultrasoincated tumor had higher Dox concentrations at 30 min, compared to bilateral noninsonated controls.
  • From 24 h to 7 days, concentrations remained highest in tumors, regardless of whether they received US or not.
  • Comparison of insonated and noninsonated tumors showed 50% more Dox in the insonated tumor at 30 min posttreatment.
  • Four weekly treatment produced additional Dox accumulation in the myocardium but not in liver, skeletal leg muscle, or tumors compared to single treatment.
  • Controls showed that neither US nor the empty carrier impacted tumor growth.
  • This study shows that US causes more release of drug at the targeted tumor.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 20166203.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098138; United States / NCI NIH HHS / CA / R01 CA098138-03; United States / NCI NIH HHS / CA / R01CA98138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Micelles; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ NIHMS229101; NLM/ PMC4533826
  •  go-up   go-down


41. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M: [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res; 2007 Nov 15;13(22 Pt 1):6610-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eleven patients with primary diagnosis of SCCHN were examined.
  • After injection of 140 to 200 MBq [(18)F]Galacto-RGD, static emission scans 60 min post injection from the head to the abdomen (n = 11) and dynamic scans >60 min covering the tumor region (n = 6) for kinetic modeling were acquired.
  • Standardized uptake values (SUV) were measured in tumors, muscle and oral mucosa.
  • Image fusion with magnetic resonance imaging and/or computed tomography (CT) scans (n = 8) and calculation of tumor subvolumes based on SUVs was done using the iPlan software (BrainLAB).
  • RESULTS: [(18)F]Galacto-RGD PET identified 10 of 12 tumors, with SUVs ranging from 2.2 to 5.8 (mean, 3.4 +/- 1.2).
  • Two tumors <5 mm were missed.
  • Tumor/blood and tumor/muscle ratios were 2.8 +/- 1.1 and 5.5 +/- 1.6, respectively.
  • Tumor kinetics was consistent with a two-tissue compartmental model with reversible specific binding.
  • Immunohistochemistry confirmed alphavbeta3 expression in all tumors with alphavbeta3 being located on the microvessels in all specimens and additionally on tumor cells in one specimen.
  • Image fusion of [(18)F]Galacto-RGD PET with magnetic resonance imaging/multislice CT and definition of tumor subvolumes was feasible in all cases.
  • Image fusion and definition of tumor subvolumes is feasible.
  • [MeSH-major] Carcinoma, Squamous Cell / blood supply. Head and Neck Neoplasms / blood supply. Integrin alphaVbeta3 / analysis. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006761.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Peptides, Cyclic; 0 / Radiopharmaceuticals; 0 / fluorogalacto-RGD; X2RN3Q8DNE / Galactose
  •  go-up   go-down


42. Gao ZR, Zhang YX, Zhang KJ: [Use of 99mTc-survivin antisense oligonucleotide in diagnosis of hepatocellular carcinoma: an experiment with mice]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of 99mTc-survivin antisense oligonucleotide in diagnosis of hepatocellular carcinoma: an experiment with mice].
  • RESULTS: Tumor lesion was early detected with (99m)Tc-survivin ASON and the lesion image showed up at 0.5 h postinjection.
  • The accumulation of (99m)Tc-survivin ASON in tumor tissue gradually increased and reached the top at 4 h postinjection.
  • The %ID/g (percentage of injected dose per gram of tissue) of (99m)Tc-survivin ASON in tumor tissue at 4 h postinjection was 0.69% +/- 0.11%.
  • And the ratios of tumor to muscle were 3.35 +/- 0.57 in biodistribution study and 2.48 +/- 0.44 in antisense imaging study.
  • But the %ID/g of (99m)Tc-survivin SON (sense oligonucleotide) in tumor tissue was only 0.17% +/- 0.01% at 4 h postinjection.
  • And the ratios of tumor to muscle were 0.74 +/- 0.04 in biodistribution study and 1.15 +/- 0.36 in antisense imaging study.
  • Both results of %ID/g of tumor tissue and ratio of tumor to muscle in SON group were significantly lower than those in ASON group at every check-time (P < 0.01).
  • Furthermore, the tumor imaging was diminished in nude mice pretreated with unlabeled survivin ASON, and the ratio of tumor to muscle was only 0.93 +/- 0.23 at 4 h postinjection and significantly lower than 2.48 +/- 0.44 in nude mice untreated (P < 0.01).
  • CONCLUSION: The accumulation of (99m)Tc-survivin ASON in hepatocellular carcinoma tissue is specific.
  • The antisense imaging with (99m)Tc-survivin ASON may be a promising method for diagnosis of hepatocellular carcinoma.
  • [MeSH-major] Carcinoma, Hepatocellular / radionuclide imaging. Liver Neoplasms / radionuclide imaging. Technetium
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Mice. Mice, Inbred Strains. Mice, Nude. Oligonucleotides, Antisense

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321225.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 7440-26-8 / Technetium
  •  go-up   go-down


43. Zhang K, An R, Gao Z, Zhang Y, Aruva MR: Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13. Nucl Med Biol; 2006 May;33(4):505-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The NT analogue (Nalpha-His)Ac-NT(8-13) was synthesized such that histidine was attached at the N-terminus.
  • Biodistribution and imaging with 99mTc-(Nalpha-His)Ac-NT(8-13) were performed at 4 and 12 h postinjection, and tissue distribution and imaging after receptor blocking were carried out at 4 h in nude mice bearing human SCLC tumor.
  • Tumor-to-muscle ratio was 3.35+/-1.01 at 4 h and 4.20+/-1.35 at 12 h postinjection.
  • In the receptor-blocking group treated with unlabeled (Nalpha-His)Ac-NT(8-13), tumor-to-muscle ratio at 4 h was 1.25+/-0.55.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Small Cell / metabolism. Carcinoma, Small Cell / radionuclide imaging. Neurotensin / pharmacokinetics. Peptide Fragments / pharmacokinetics. Receptors, Neurotensin / metabolism. Technetium / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Feasibility Studies. Female. Humans. Isotope Labeling / methods. Metabolic Clearance Rate. Mice. Mice, Nude. Neoplasm Proteins / metabolism. Organ Specificity. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • Genetic Alliance. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720242.001).
  • [ISSN] 0969-8051
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Peptide Fragments; 0 / Radiopharmaceuticals; 0 / Receptors, Neurotensin; 39379-15-2 / Neurotensin; 60482-95-3 / neurotensin (8-13); 7440-26-8 / Technetium
  •  go-up   go-down


44. Ip PP, Cheung AN, Clement PB: Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol; 2009 Jul;33(7):992-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
  • BACKGROUND: The current World Health Organization classification indicates that a uterine smooth muscle tumor that cannot be histologically diagnosed as unequivocally benign or malignant should be termed "smooth muscle tumor of uncertain malignant potential" (STUMP).
  • STUMPs represent a heterogeneous group of rare tumors that have been the subject of only a few published studies, some of which lack detailed clinicopathologic details and/or follow-up data.
  • More recently, it has been suggested that immunohistochemical staining may be helpful in the diagnosis of STUMPs.
  • DESIGN: The clinicopathologic features of 16 cases of STUMP that exhibited usual smooth muscle differentiation, diagnosed between 1992 and 2006 from 11 hospitals, were studied and classified into 4 subgroups using terminology and criteria described by Stanford investigators.
  • RESULTS: The tumors were classified as follows: 6 as "atypical leiomyoma with limited experience", 7 as "smooth muscle tumor of low malignant potential", 2 as "atypical leiomyoma, low risk of recurrence," and 1 as "mitotically active leiomyoma, limited experience."
  • Only 2 tumors recurred, at 15 and 51 months, respectively; both were atypical leiomyoma with limited experience (multifocal moderate-to-severe atypia, no tumor cell necrosis, and mitotic counts of 4 and 5 mitotic figures /10 high-power fields, respectively).
  • Both tumors had areas that were indistinguishable from benign leiomyoma and both had diffuse immunoreactivity for p16 and p53.
  • Six other tumors that had focal staining for these markers all had a benign outcome.
  • All the other patients were alive and disease-free.
  • CONCLUSIONS: This and other studies suggest that uterine tumors classified as STUMPs using criteria proposed by Stanford investigators are usually clinically benign but should be considered tumors of low malignant potential because they can occasionally recur, in some cases, years after hysterectomy.
  • After a mean follow-up of 80.8 months, only 2 of 16 tumors in this study recurred.
  • Both of the latter tumors fulfilled the criteria for atypical leiomyoma with limited experience.
  • Notably, the 2 recurrent tumors were the only ones that were strongly immunoreactive for p16 and p53, supporting earlier observations that these markers may be helpful in the prediction of the behavior of STUMPs.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Ubiquitin-Protein Ligases / biosynthesis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417585.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


45. He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, Zhang N, Seo Y, VanBrocklin HF, Liu B: Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med; 2010 Mar;51(3):427-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the tumor targeting of an internalizing human antibody fragment, a small-size platform, to provide high contrast in a mouse model of human prostate carcinoma.
  • METHODS: A prostate tumor-targeting single-chain antibody fragment (scFv), UA20, along with a nonbinding control scFv, N3M2, were labeled with (99m)Tc and evaluated for binding and rapid internalization into human prostate tumor cells in vitro and tumor homing in vivo using xenograft models.
  • The labeled UA20 scFv was taken up specifically by prostate tumor cells.
  • Internalization was rapid, because incubation at 37 degrees C for less than 1 h resulted in 93% internalization of total cell-associated scFvs. In animal studies, SPECT/CT showed significant tumor uptake as early as 1 h after injection.
  • At 3 h after injection, tumor uptake was 4.4 percentage injected dose per gram (%ID/g), significantly greater than all organs or tissues studied (liver, 2.7 %ID/g; other organs or tissues, <1 %ID/g), except the kidneys (81.4 %ID/g), giving tumor-to-blood and tumor-to-muscle ratios of 12:1 and 70:1, respectively.
  • In contrast, the control antibody exhibited a tumor uptake of only 0.26 %ID/g, similar to that of muscle and fat.
  • Tumor-specific targeting was evidenced by reduced tumor uptake of nearly 70% on administration of a 10-fold excess of unlabeled UA20 scFv.
  • CONCLUSION: The UA20 scFv showed rapid and specific internalization in prostate tumor cells in vitro and accumulation in prostate tumor xenografts in vivo, demonstrating the potential for future development for prostate cancer imaging and targeted therapy.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4022-8 [15930336.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8397-405 [16166318.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7454-61 [16243819.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):448-62 [16285907.001]
  • [Cites] Nat Rev Drug Discov. 2005 Dec;4(12):1015-26 [16341066.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):533-40 [16321969.001]
  • [Cites] Nat Clin Pract Urol. 2006 Apr;3(4):216-25 [16607370.001]
  • [Cites] Mol Cell Proteomics. 2006 Dec;5(12):2364-73 [16982673.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):540-7 [17290063.001]
  • [Cites] J Immunother. 2007 May-Jun;30(4):396-405 [17457214.001]
  • [Cites] Nat Protoc. 2006;1(4):2048-60 [17487194.001]
  • [Cites] J Nucl Med. 2007 Aug;48(8):1379-89 [17631555.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2737-46 [17938267.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):2012-20 [17660511.001]
  • [Cites] Mol Cancer Ther. 2008 Mar;7(3):569-78 [18319332.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3036-43 [18483369.001]
  • [Cites] Prostate. 2008 Jun 15;68(9):955-64 [18361407.001]
  • [Cites] J Nucl Med. 2008 Jul;49(7):1066-74 [18552139.001]
  • [Cites] J Med Chem. 2008 Aug 14;51(15):4504-17 [18637669.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7488-96 [19010866.001]
  • [Cites] J Med Chem. 2008 Dec 25;51(24):7933-43 [19053825.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1570-7 [19221091.001]
  • [Cites] Protein Eng Des Sel. 2009 Mar;22(3):209-16 [18957406.001]
  • [Cites] J Nucl Med. 2009 Mar;50(3):435-43 [19223400.001]
  • [Cites] J Nucl Med. 2009 Apr;50(4):606-11 [19289418.001]
  • [Cites] J Mol Med (Berl). 2009 May;87(5):507-14 [19219419.001]
  • [Cites] J Nucl Med. 2009 May;50(5):781-9 [19372467.001]
  • [Cites] Mol Imaging Biol. 2009 May-Jun;11(3):159-66 [19034582.001]
  • [Cites] Eur J Radiol. 2009 May;70(2):212-26 [18993004.001]
  • [Cites] J Nucl Med. 2009 Sep;50(9):1492-9 [19690041.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4750-5 [11406547.001]
  • [Cites] Biochim Biophys Acta. 2002 Aug 19;1591(1-3):109-118 [12183061.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 18;307(1):8-14 [12849974.001]
  • [Cites] Mol Imaging. 2002 Apr-Jun;1(2):96-101 [12920850.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):704-10 [14744788.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Immunotechnology. 1996 Feb;2(1):21-36 [9373325.001]
  • [Cites] Prostate. 1998 Nov 1;37(3):140-8 [9792131.001]
  • [Cites] Nat Biotechnol. 1999 Sep;17(9):897-901 [10471933.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2591-6 [15814638.001]
  • (PMID = 20150269.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA137429; United States / NCI NIH HHS / CA / R21 CA137429-01A1; United States / NCI NIH HHS / CA / R01 CA135358-02; United States / NCI NIH HHS / CA / R01 CA135358; United States / NCI NIH HHS / CA / CA137429-01A1; United States / NCI NIH HHS / CA / R01 CA118919-01; United States / NCI NIH HHS / CA / CA118919-01; United States / NCI NIH HHS / CA / R01 CA135358-01; United States / NCI NIH HHS / CA / CA135358-02; United States / NCI NIH HHS / CA / R01 CA118919; United States / NCI NIH HHS / CA / CA135358-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Fragments; 0 / Organotechnetium Compounds; 0 / Single-Chain Antibodies
  • [Other-IDs] NLM/ NIHMS174420; NLM/ PMC2832590
  •  go-up   go-down


46. Agaimy A, Wünsch PH: Distribution of neural cell adhesion molecule (NCAM/CD56) in gastrointestinal stromal tumours and their intra-abdominal mesenchymal mimics. J Clin Pathol; 2008 Apr;61(4):499-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of neural cell adhesion molecule (NCAM/CD56) in gastrointestinal stromal tumours and their intra-abdominal mesenchymal mimics.
  • BACKGROUND: The distribution and reactivity pattern of neural cell adhesion molecule (NCAM/CD56) in gastrointestinal stromal tumours (GISTs) and their mesenchymal mimics have not been investigated in the KIT era.
  • METHODS: 275 histologically and immunohistochemically well characterised primary and metastatic intra-abdominal mesenchymal lesions were analysed by conventional immunohistochemistry, with emphasis on GIST and GI smooth muscle neoplasms.
  • Except for a subset of epithelioid gastric and high-grade rectal GISTs, CD56 expression is rare in GISTs, contrasting with true leiomyomatous and neurogenic neoplasms.
  • CD56 plays a limited role in the differential diagnosis of GIST.
  • [MeSH-major] Antigens, CD56 / metabolism. Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Diagnosis, Differential. Fibrosarcoma / diagnosis. Fibrosarcoma / metabolism. Humans. Melanoma / diagnosis. Melanoma / metabolism. Melanoma / secondary. Neoplasms, Muscle Tissue / diagnosis. Neoplasms, Muscle Tissue / metabolism. Nerve Sheath Neoplasms / metabolism. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923471.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


47. Morimoto T, Obata T, Ohno T, Suzuki Y, Ikehira H, Suhara T, Furukawa S, Tsujii H, Nakano T: Phosphorous-31 magnetic resonance spectroscopy of cervical cancer using transvaginal surface coil. Magn Reson Med Sci; 2005 Dec 31;4(4):197-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 50-year-old woman with uterine cervical cancer (International Federation of Gynecology and Obstetrics [FIGO] stage IIIb), (31)P MRS with the new coil clearly differentiated the low intensity of phosphocreatinine (PCr) and high intensity of phosphomonoester (PME) in tumor from those in muscle.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Magnetic Resonance Spectroscopy / instrumentation. Magnetic Resonance Spectroscopy / methods. Uterine Cervical Neoplasms / diagnosis


48. Corot C, Robert P, Lancelot E, Prigent P, Ballet S, Guilbert I, Raynaud JS, Raynal I, Port M: Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med; 2008 Dec;60(6):1337-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting.
  • The objective of this study was to evaluate the potential of a high-relaxivity macromolecular gadolinium (Gd) chelate to target folate receptors (FRs).
  • Binding affinity, in vivo biodistribution studies in KB tumor-bearing mice at 1, 4, and 24 h, and dynamic contrast-enhanced (DCE)-MRI (2.35 T) over 4 h were assessed.
  • Tumor/muscle (T/M) uptake was 5.4 +/- 1.0, 4 h after injection of 15 micromol/kg.
  • While this high-relaxivity folate-Gd chelate has demonstrated its potential capacity to target in vivo FR on tumors, the sensitivity is probably limited to a certain extent by the saturation of the FR and by the decrease in the apparent relaxivity of the internalized part of P866 in the tumor cells.
  • [MeSH-major] Carrier Proteins / metabolism. Drug Delivery Systems / methods. Gadolinium DTPA / pharmacokinetics. Nasopharyngeal Neoplasms / metabolism. Nasopharyngeal Neoplasms / radionuclide imaging. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Chelating Agents / pharmacokinetics. Contrast Media / pharmacokinetics. Folate Receptors, GPI-Anchored. Humans. Metabolic Clearance Rate. Mice. Organ Specificity. Tissue Distribution

  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025883.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Chelating Agents; 0 / Contrast Media; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


49. Wilson DF, Lee WM, Makonnen S, Apreleva S, Vinogradov SA: Oxygen pressures in the interstitial space of skeletal muscle and tumors in vivo. Adv Exp Med Biol; 2008;614:53-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxygen pressures in the interstitial space of skeletal muscle and tumors in vivo.
  • Oxyphor G3 was injected along "tracks" in the tissue using a small needle (30gage or less) and remained in the pericellular space, allowing oxygen measurements for several hours with a single injection.
  • In normal muscle, in the lower oxygen pressure region of the histograms (capillary bed) the oxygen pressure difference was small.
  • In tumors, the oxygen pressures in the two spaces were similar but with large differences among tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1177-84 [15772057.001]
  • [Cites] J Appl Physiol (1985). 2005 Apr;98(4):1503-10 [15579567.001]
  • [Cites] Org Lett. 2005 Apr 28;7(9):1761-4 [15844900.001]
  • [Cites] Appl Opt. 2005 Sep 1;44(25):5239-48 [16149347.001]
  • [Cites] J Appl Physiol (1985). 2006 Dec;101(6):1648-56 [16888050.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):H1831-40 [10564137.001]
  • [Cites] Respir Physiol. 2001 May;126(1):53-63 [11311310.001]
  • [Cites] Comp Biochem Physiol A Mol Integr Physiol. 2002 May;132(1):75-85 [12062194.001]
  • [Cites] Methods Enzymol. 2002;352:3-31 [12125356.001]
  • [Cites] Anal Biochem. 2002 Nov 15;310(2):191-8 [12423638.001]
  • [Cites] Adv Exp Med Biol. 2003;530:569-75 [14562753.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):677-86 [15130295.001]
  • [Cites] Microcirculation. 2004 Jun;11(4):317-26 [15280071.001]
  • [Cites] Physiologist. 1971 May;14(2):69-82 [5088084.001]
  • [Cites] Microvasc Res. 1973 May;5(3):254-62 [4709724.001]
  • [Cites] Microvasc Res. 1976 Jul;12(1):59-70 [967026.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5476-82 [3571219.001]
  • [Cites] J Biol Chem. 1988 Feb 25;263(6):2712-8 [2830260.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1649-51 [3420417.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1676-80 [8184947.001]
  • [Cites] Biophys J. 1994 Nov;67(5):2048-59 [7858142.001]
  • [Cites] Biophys J. 1996 Apr;70(4):1609-17 [8785320.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 2):H2233-40 [9176291.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6590-5 [9618456.001]
  • [Cites] Adv Exp Med Biol. 1998;454:367-74 [9889913.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1717-22 [10206282.001]
  • [Cites] Am J Physiol. 1999 Jun;276(6 Pt 1):G1515-20 [10362656.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):203-13 [15798296.001]
  • (PMID = 18290314.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS-31465; United States / NINDS NIH HHS / NS / R01 NS031465-14; United States / NHLBI NIH HHS / HL / R01 HL081273-02; United States / NINDS NIH HHS / NS / R01 NS031465; United States / NINDS NIH HHS / NS / NS031465-13A2; United States / NHLBI NIH HHS / HL / R01 HL081273; United States / NHLBI NIH HHS / HL / HL081273-02; United States / NINDS NIH HHS / NS / NS031465-15; United States / NHLBI NIH HHS / HL / R01 HL081273-01A1; United States / NCI NIH HHS / CA / U54 CA105008; United States / NINDS NIH HHS / NS / R01 NS031465-15; United States / NHLBI NIH HHS / HL / HL081273-01A1; United States / NINDS NIH HHS / NS / R01 NS031465-13A2; United States / NCI NIH HHS / CA / U54 CA105008-01; United States / NINDS NIH HHS / NS / NS031465-14; United States / NHLBI NIH HHS / HL / HL081273
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / Metalloporphyrins; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ NIHMS79505; NLM/ PMC2590629
  •  go-up   go-down


50. Chen MH, Chang CH, Chang YJ, Chen LC, Yu CY, Wu YH, Lee WC, Yeh CH, Lin FH, Lee TW, Yang CS, Ting G: MicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice. Anticancer Res; 2010 Jan;30(1):65-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the in vivo nuclear imaging, pharmacokinetics and biodistribution of administered nanoliposomes were investigated as drug and radionuclide carriers for targeting solid tumor via intravenous (i.v.) administration.
  • The radiotherapeutics ((188)Re-liposome) and radiochemotherapeutics ((188)Re-DXR-liposome) were i.v. administered to nude mice bearing human HT-29 colorectal adenocarcinoma xenografts. (188)Re-liposome and (188)Re-DXR-liposomes show similar biodistribution profile; both have higher tumor uptake, higher blood retention time, and lower excretion rate than (188)Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylenediamine (BMEDA).
  • In contrast to tumor uptake, the area under the curve (AUC) value of tumor for (188)Re-liposome and (188)Re-DXR-liposome was 16.5- and 11.5-fold higher than that of free (188)Re-BMEDA, respectively.
  • Additionally, (188)Re-liposome and (188)Re-DXR-liposome had a higher tumor-to-muscle ratio at 24 h (14.4+/-2 .7 and 17.14+/-4.1, respectively) than (188)Re-BMEDA (1.6+/-0.1).
  • The tumor targeting and distribution of (188)Re-(DXR)-liposome (representing (188)Re-DXR-liposome and (188)Re-liposome) can also be acquired by signal photon-emission computed tomography/computed tomography images as well as whole body autoradiograph.
  • These results suggest that (188)Re-(DXR)-liposomes are potentially promising agents for passive targeting treatment of malignant disease.
  • [MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Doxorubicin / analogs & derivatives. Nanoparticles / administration & dosage. Radioisotopes / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics. Rhenium / pharmacokinetics
  • [MeSH-minor] Animals. HT29 Cells. Humans. Liposomes / administration & dosage. Liposomes / pharmacokinetics. Mice. Mice, Nude. Organometallic Compounds / administration & dosage. Organometallic Compounds / pharmacokinetics. Tissue Distribution. Tomography, Emission-Computed, Single-Photon / methods. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150618.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Liposomes; 0 / Organometallic Compounds; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 7440-15-5 / Rhenium; 80168379AG / Doxorubicin
  •  go-up   go-down


51. Akizawa H, Zhao S, Takahashi M, Nishijima K, Kuge Y, Tamaki N, Seki K, Ohkura K: In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging. Nucl Med Biol; 2010 May;37(4):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging.
  • INTRODUCTION: The expression of thymidine phosphorylase (TP) is closely associated with angiogenesis, tumor invasiveness and activation of antitumor agents.
  • We evaluated radioiodinated 5-iodo-6-[(2-iminoimidazolidinyl)methyl]uracil ([(125)I]IIMU) having high TP-inhibitory potency as the new radiotracer for SPECT targeting of TP expression in tumors.
  • METHODS: The characteristics of the radioiodinated TP inhibitor IIMU were determined by evaluating the uptake by tumor cells in vitro and by biodistribution studies in vivo.
  • The distribution of the radiotracer and the extent of TP-specific uptake by tumors were evaluated by a counting method in tumor-bearing mice.
  • In vivo distribution of the radiotracer in A431 tumor-bearing mice revealed tumor/blood and tumor/muscle activity uptake ratios of 36 and 106, respectively, at 3 h after the radiotracer injection.
  • On using low TP-expressing tumors and TP blocking studies as controls, minor TP-specific accumulation of the radiotracer was detected in these studies.
  • CONCLUSION: According to the binding of radioiodinated IIMU to the angiogenic enzyme TP, it can be concluded that radioiodinated IIMU might be suitable as a SPECT tracer for tumor imaging.
  • [MeSH-major] Enzyme Inhibitors. Neoplasms / blood supply. Neoplasms / radionuclide imaging. Neovascularization, Pathologic / enzymology. Thymidine Phosphorylase / antagonists & inhibitors. Thymidine Phosphorylase / metabolism. Uracil / analogs & derivatives
  • [MeSH-minor] Animals. Biological Transport. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Iodine Radioisotopes. Mice. Tomography, Emission-Computed, Single-Photon

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20447553.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-iodo-6-((2-iminoimidazolidinyl)methyl)uracil; 0 / Enzyme Inhibitors; 0 / Iodine Radioisotopes; 56HH86ZVCT / Uracil; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


52. Min KW: Stromal elements for tumor diagnosis: a brief review of diagnostic electron microscopic features. Ultrastruct Pathol; 2005 May-Aug;29(3-4):305-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal elements for tumor diagnosis: a brief review of diagnostic electron microscopic features.
  • Tumor diagnosis mainly depends on the appearance of the tumor cells in recapitulating the appearance of primordial cells from which they arise.
  • However, certain tumors may present with specific stromal changes that may assist/enhance the diagnosis.
  • In mesenchymal tissue, different types of interface can be found in different types of mesenchymal tissue.
  • In epithelial tissue, cells in a functional unit are enclosed within a well-defined external lamina (EL).
  • In malignant epithelial tumors, EL can become increasingly indistinct as tumors become less differentiated, and one has to look for it diligently.
  • In contrast to epithelial tissue, mesenchymal tissue is usually characterized by the stromal elements they produce.
  • Thus, tumors deriving from mesenchymal cells known to have external lamina such as muscle cells and Schwann cells tend to show total enclosure of cells by external lamina.
  • In malignant muscle tumors, external lamina production can be focally present and found only by diligent search.
  • In Schwann cell tumors, the presence of EL is prominent in low-grade tumors and more irregular and variable in malignant tumors.
  • Similar features are seen in ossifying fibromyxoid tumors.
  • Finding them in spindle cell tumors justifies a diagnosis of myofibroblastomas.
  • There have been several stromal changes diagnostic for certain tumors found only by electron microscopy.
  • Fibrous long-spaced collagen (known as Luse bodies) is diagnostic for peripheral nerve sheath tumors, but they can rarely be found in other tumors.
  • Spiny collagen and amianthoid fibers are interesting collagen fibrils and their diagnostic value is questionable.
  • They were originally described in neurogenic tumors and small intestinal stromal tumors with features of gastrointestinal autonomic nerve tumors (GANT).
  • Although there have been a few sporadic case reports of the presence of skeinoid fibers in nonneurogenic tumors, the frequent presence of SF in spindle cell tumors signifies their neurogenic nature in this authors' experience.
  • An exception to this is that SF can be a constant element of rare ciliary body tumors known as ciliary mesectodermal leiomyomas, in which tumor cells show some resemblance to smooth muscle as well as Schwann cells.
  • In addition to SF, several other types of peculiar crystallized collagen were observed in GANT tumors, particularly those with multiple tumor syndromes such as neurofibromatosis and Carney's triad.
  • This stromal change simulating a tiger skin pattern is also seen in primitive neuroectodermal tumors and malignant melanomas.
  • In view of continually new discoveries of stromal changes that can be used for the differential diagnosis of tumors, the importance of close evaluation of stromal elements of tumors, and diligent application of electron microscopy in tumor diagnosis cannot be overemphasized.
  • [MeSH-major] Neoplasms / diagnosis. Neoplasms / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036885.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


53. Xiong T, Peng H, Chen G, Yuan Y: The expression and activity of MMPs are increased in residual tumor tissues after the termination of immunotherapy. J Huazhong Univ Sci Technolog Med Sci; 2008 Aug;28(4):375-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression and activity of MMPs are increased in residual tumor tissues after the termination of immunotherapy.
  • To investigate the invasive ability of the residual tumor cells after immunotherapy and explore the feasible approach suppressing the invasion, mice were inoculated with B16 cells, and then treated by gene therapy with p4-1BBL/psPD-1 or IFN-gamma.
  • The production and activities of MMP-9 and MMP-2 in residual tumor tissues were analyzed with gelatin zymography 1 day and 7 days after the termination of the immunotherapy.
  • The invasion of tumor to muscular tissue was analyzed.
  • Gene therapy with CH50 was used to suppress the invasive growth of tumor.
  • The response of tumor cells to ECM molecules was intensified after the removal of IFN-gamma, resulting in significant increase of both the production and activities of MMP-9 and MMP-2, and the increased invasion of tumor.
  • Gene therapy with CH50 effectively suppressed the invasive growth of tumor.
  • It is concluded that the termination of immunotherapy may result in a higher metastatic potential of residual tumor cells.
  • Suppressing tumor invasion by suitable treatment will improve the efficacy of immunotherapy.
  • [MeSH-minor] Animals. Combined Modality Therapy. Female. Fibronectins / therapeutic use. Genetic Therapy / methods. Interferon-gamma / therapeutic use. Mice. Mice, Inbred C57BL. Neoplasm Invasiveness / prevention & control. Neoplasm Transplantation. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2004 Oct 15;173(8):4919-28 [15470033.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Mar;27(3):164-6 [15946567.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1823-30 [17325342.001]
  • [Cites] Cancer Immunol Immunother. 2003 Feb;52(2):97-106 [12594573.001]
  • [Cites] Cancer Gene Ther. 2004 Mar;11(3):215-26 [14671675.001]
  • [Cites] Cancer Immunol Immunother. 2005 Sep;54(9):891-7 [15776283.001]
  • [Cites] J Immunol. 2001 Mar 15;166(6):3890-9 [11238633.001]
  • [Cites] J Gene Med. 2006 Feb;8(2):129-37 [16288496.001]
  • [Cites] J Leukoc Biol. 2000 Jul;68(1):1-8 [10914483.001]
  • [Cites] Nat Med. 1998 Apr;4(4):408-14 [9546785.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):184-92 [17330234.001]
  • [Cites] Exp Dermatol. 2003 Apr;12(2):109-25 [12702139.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):361-5 [9766572.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2006 Nov;28(11):815-9 [17416001.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3725-33 [14500672.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55297-307 [15448160.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8869-77 [16204058.001]
  • (PMID = 18704294.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CH50 recombinant polypeptide; 0 / Fibronectins; 0 / Recombinant Proteins; 82115-62-6 / Interferon-gamma; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.24 / Mmp2 protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.35 / Mmp9 protein, mouse
  •  go-up   go-down


54. Hu J, Qin G, Zhang Y, An R, Lan X: (99m)Tc-YIGSR as a receptor tracer in imaging the Ehrlich ascites tumor-bearing mice as compared with (99m)Tc-MIBI. J Huazhong Univ Sci Technolog Med Sci; 2007 Aug;27(4):471-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (99m)Tc-YIGSR as a receptor tracer in imaging the Ehrlich ascites tumor-bearing mice as compared with (99m)Tc-MIBI.
  • The validity of (99m)Tc-YIGSR, a novel receptor radio-tracer, in imaging the Ehrlich ascites tumor was evaluated.
  • The mice of tumor group were intravenously injected 1-2 mCi of (99m)Tc-YIGSR or (99m)Tc-MIBI via caudal vein, immobilized and imaged under a Gamma camera.
  • The imagological study revealed obvious tumor accumulation of (99m)Tc-YIGSR 15 min after the injection, and the uptake peaked after 3 h with a tumor-to-muscle ratio (T/M) of 11.36.
  • The radio-tracer was slowly cleared up and resulted in a T/M of 3.01 at the 8th h after the injection.
  • As for blocked group, the tumor uptake of radiotracer was significantly lower, with the highest T/M being 4.61 after 3 h and 0.89 after 8 h.
  • The T/M was significantly higher in tumor group than in inflammatory group or control group (P<0.001).
  • It is concluded that YIGSR can be successfully radiolabelled by using S-Acetly-NH(3)-MAG(3). (99m)Tc-YIGSR has many advantages in tumor imaging, such as quick and clear visualization, high sensitivity and specificity, and satisfactory target/non-target ratio (N/NT).
  • It promises to be tumor radio-tracer.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / diagnostic imaging. Radiopharmaceuticals. Receptors, Laminin / metabolism. Technetium Tc 99m Mertiatide. Technetium Tc 99m Sestamibi

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15996-6002 [10347148.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jan;80(2):444-8 [6300843.001]
  • [Cites] Invasion Metastasis. 1996;16(6):322-9 [9371232.001]
  • [Cites] Cell Adhes Commun. 1994 Jul;2(3):201-9 [7827956.001]
  • [Cites] Biochemistry. 1987 Nov 3;26(22):6896-900 [2962631.001]
  • [Cites] Int J Dev Biol. 1994 Mar;38(1):121-6 [8074991.001]
  • [Cites] J Nucl Med. 1997 Dec;38(12 ):1940-4 [9430474.001]
  • [Cites] Arch Biochem Biophys. 1998 Oct 15;358(2):283-90 [9784241.001]
  • [Cites] Nucl Med Biol. 1997 Jul;24(5):425-32 [9290078.001]
  • (PMID = 17828515.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radioactive Tracers; 0 / Radiopharmaceuticals; 0 / Receptors, Laminin; 36ITO9SKQJ / Technetium Tc 99m Mertiatide; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


55. af Klinteberg C, Pifferi A, Andersson-Engels S, Cubeddu R, Svanberg S: In vivo absorption spectroscopy of tumor sensitizers with femtosecond white light. Appl Opt; 2005 Apr 10;44(11):2213-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo absorption spectroscopy of tumor sensitizers with femtosecond white light.
  • A system based on a femtosecond white-light continuum and a streak camera was used for recordings of the in vivo absorption spectra of the tumor-seeking agent disulphonated aluminum phthalocyanine.
  • Measurements for different drug doses were performed on tumor tissue (muscle-implanted adenocarcinoma) and normal muscle tissue in rats.
  • It was found that the shape of the spectrum is tissue dependent.
  • The peak of the absorption spectrum is blueshifted in tumor tissue as compared with the muscle.
  • Thus the contrast in the drug-related absorption can be altered by up to a factor of 2 from the primary drug molecular-concentration contrast between normal muscle and tumor by the proper selection of the illumination wavelength.
  • [MeSH-major] Colonic Neoplasms / metabolism. Indoles / analysis. Indoles / pharmacokinetics. Organometallic Compounds / analysis. Organometallic Compounds / pharmacokinetics. Spectroscopy, Fourier Transform Infrared / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15835366.001).
  • [ISSN] 0003-6935
  • [Journal-full-title] Applied optics
  • [ISO-abbreviation] Appl Opt
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 0 / Organometallic Compounds; 0 / Radiation-Sensitizing Agents; 47822-79-7 / aluminum phthalocyanine
  •  go-up   go-down


56. Al-Daraji WI, Salman WD, Nakhuda Y, Zaman F, Eyden B: Primary smooth muscle tumor of the pleura: a clinicopathological case report with ultrastructural observations and a review of the literature. Ultrastruct Pathol; 2005 Sep-Oct;29(5):389-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary smooth muscle tumor of the pleura: a clinicopathological case report with ultrastructural observations and a review of the literature.
  • Primary smooth muscle tumor of the pleura is exceptionally rare.
  • The authors describe a primary smooth muscle tumor of the pleura that was discovered incidentally on chest X-ray in a 73-year-old man.
  • Computerized tomography (CT) guided needle cores from the pleura showed a primary smooth muscle tumor of undetermined malignant potential.
  • Further excision of the whole tumor showed an intimate relation to pleura, and the diagnosis of leiomyosarcoma was made.
  • The clinical, radiological, histopathological, immunohistochemical, and ultrastuctural findings were consistent with a primary smooth muscle tumor of the pleura.
  • This is the seventh case in the literature of a primary smooth muscle tumor of the pleura, which, to the best of the authors' knowledge, is the first such case of the pleura to be diagnosed on CT-guided needle biopsy.
  • In conclusion, this method of investigation is recommended since it is minimally invasive but has a rewarding yield in providing the most likely diagnosis, predicting prognosis, and management planning.
  • [MeSH-major] Leiomyosarcoma / pathology. Mediastinal Neoplasms / pathology. Pleural Neoplasms / pathology. Smooth Muscle Tumor / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Thoracotomy. Tomography, X-Ray Computed

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for smooth muscle tumor .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257865.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


57. Gajda M, Welzel C, Holzhausen HJ, Jamali Y, Schrom T, Hauptmann S, Bloching M: [Multifocal adult rhabdomyoma of the neck: a rare entity]. Otolaryngol Pol; 2005;59(6):883-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracardiac rhabdomyoma comprise 2% of all tumors of skeletal muscle differentiation.
  • The pathogenesis of this benign striated muscle tumor is still unclear.
  • These slow-growing tumors remain asymptomatic for a long period.
  • The diagnosis of head and neck rhabdomyoma is based on histology and immunhistochemical studies.
  • The differential diagnoses of rhabdomyoma in adults are myoblastoma or Abrikossof tumor, reticulohistiocytoma, rhabdomyosarcoma and hibernoma.
  • Although adult rhabdomyomas have a distinct histology, they often are mistaken for a variety of other lesions, particularly Abrikossof tumor.
  • Immunhistochemically, all applied muscular markers were positive.
  • Electron microscopic studies confirmed the tumor's myogenic origin.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Rhabdomyoma / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Muscle, Skeletal / pathology. Muscle, Skeletal / surgery. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521457.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 16
  •  go-up   go-down


58. Tsai KC, Liao ZK, Yang SJ, Lin WL, Shieh MJ, Hwang LH, Chen WS: Differences in gene expression between sonoporation in tumor and in muscle. J Gene Med; 2009 Oct;11(10):933-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in gene expression between sonoporation in tumor and in muscle.
  • US can temporarily change the permeability of a cell membrane and thus enhance the delivery of naked DNA into cells.
  • In the present study, the efficiencies of gene expression mediated by US delivery in orthotopic liver tumor, subcutaneous tumor and muscle tissue were evaluated by changing the contrast agent concentrations and US exposure durations.
  • RESULTS: The results obtained showed that the optimal condition was 50% SonoVue for tumors and 30% for muscle, with 10 min of US exposure.
  • The expression levels of the transfected DNAs were in the order: muscle > subcutaneous tumor > orthotopic liver tumor.
  • CONCLUSIONS: The present study indicates that muscle tissue is a good target site for producing large amounts of gene products for the purpose of gene therapy.
  • [MeSH-major] Gene Expression. Liver Neoplasms, Experimental / metabolism. Liver Neoplasms, Experimental / ultrasonography. Muscle, Skeletal / metabolism. Muscle, Skeletal / ultrasonography. Transfection / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639605.001).
  • [ISSN] 1521-2254
  • [Journal-full-title] The journal of gene medicine
  • [ISO-abbreviation] J Gene Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Fluorescent Dyes; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 187348-17-0 / Interleukin-12; EC 1.13.12.- / Luciferases
  •  go-up   go-down


59. Wei CH, Qian J, Bi YW, Chen RJ, Yao YQ, Yuan YF: [Orbital solitary fibrous tumor: a clinicopathologic analysis]. Zhonghua Yan Ke Za Zhi; 2008 Aug;44(8):691-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital solitary fibrous tumor: a clinicopathologic analysis].
  • OBJECTIVE: To study clinicopathologic features, histologic characteristics, differential diagnosis and the treatment of orbital solitary fibrous tumor (SFT).
  • The location of the tumor was in the muscle cone (case 1 and case 5), medial (case 3), lateral (case 4), superior (case 2) and inferolateral (case 6) portion of the orbit, respectively.
  • Histologically, SFT displayed as a mass of spindle cells in an irregular arrangement Sometime, tumor cells could be storiform or sarciniform.
  • CONCLUSIONS: SFT is a rare orbital tumor and could be confused with other types of orbital tumors.
  • This tumor can be diagnosed by pathological and immunocytochemical studies, these characteristics can be used to differentiate it from other types of orbital tumors.
  • [MeSH-major] Fibroma / diagnosis. Fibroma / pathology. Orbital Neoplasms / diagnosis. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115630.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • Some types of mixed epithelial and stromal neoplasm are described and contrasted with carcinosarcoma.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


61. Ohira T, Okuma T, Matsuoka T, Wada Y, Nakamura K, Watanabe Y, Inoue Y: FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits. Cardiovasc Intervent Radiol; 2009 Jan;32(1):114-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits.
  • The objective of this study was to evaluate the early changes after radiofrequency ablation (RFA) in VX2 rabbit tumors implanted into the back muscles by diffusion-weighted magnetic resonance (MR) imaging and (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography ((18)F-FDG PET).
  • Percutaneous CT-guided RFA was conducted in seven rabbits with implanted VX2 tumors.
  • VX2 tumors on the other side were untreated and served as the control.
  • The mean apparent diffusion coefficient (ADC) values and radioactivity count of untreated and ablated tumors were calculated.
  • Untreated VX2 tumors showed hyperintensity on T1-, T2-, and diffusion-weighted MR images, ring-enhanced on contrast-enhanced T1-weighted imaging, and ring-shaped FDG accumulation on FDG-PET.
  • Ablated VX2 tumors showed slight hyperintensity on T1-, T2-, and diffusion-weighed images, slight enhancement on contrast-enhanced T1-weighted images, and low accumulation on FDG-PET.
  • The ADC value of ablated VX2 tumors (1.52 +/- 0.24 x 10(-3) mm(2)/s) was significantly higher than that of untreated tumors (1.09 +/- 0.12 x 10(-3); p < 0.05).
  • The tumor/muscle ratio of ablated tumors (0.5 +/- 0.3) was significantly lower than that of untreated tumors (11.6 +/- 3.2; p < 0.05).
  • Histopathological examination confirmed the lack of viable tumor cells in the ablated lesions.
  • The results indicate that both ADC value and FDG-PET are potentially useful markers for monitoring the early effects of RFA.
  • [MeSH-major] Catheter Ablation. Diffusion Magnetic Resonance Imaging / methods. Muscle Neoplasms / surgery. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Contrast Media. Disease Models, Animal. Fluorodeoxyglucose F18. Neoplasm Transplantation. Rabbits. Radiography, Interventional. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696151.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


62. Zamecnik M, Voltr L, Chlumska A: HMB45+ cells in mixed stromal-smooth muscle tumour of the uterus. Histopathology; 2006 Mar;48(4):463-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HMB45+ cells in mixed stromal-smooth muscle tumour of the uterus.
  • [MeSH-major] Endometrial Stromal Tumors / pathology. Neoplasm Proteins / analysis. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Infant, Newborn. Melanoma-Specific Antigens

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487370.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


63. Wolf G, Schindler S, Koch A, Abolmaali N: Diffusion-weighted MRI for tumour volume delineation: comparison with morphological MRI. J Med Imaging Radiat Oncol; 2010 Jun;54(3):194-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI for tumour volume delineation: comparison with morphological MRI.
  • Diffusion-weighted magnetic resonance imaging (dwMRI) is sensitive to tissue microstructure on the cellular level and may therefore help to define biological tumour subvolumes and add complementary information to morphology-based cancer treatment protocols and therapy monitoring.
  • The purpose of this study was therefore to evaluate the potential of dwMRI as compared with morphological MRI (mMRI) for tumour volume delineation using a nude rat human tumour xenograft model.
  • Sixteen tumour-bearing rats (10 H1299, six FaDu) were examined with mMRI (T2-weighted true fast imaging with steady precession (TrueFISP), T1-weighted fast low angle shot (FLASH), T2-weighted dual echo steady state (DESS)) and echo-planar dwMRI in a clinical scanner at 1.5 T.
  • For each method, we compared tumour volume and intra- and inter-observer variability of tumour outer edge delineation (disregarding intra-tumoural structure) as well as tumour signal-to-noise ratio (SNR) and tumour-to-muscle contrast-to-noise ratio (CNR).
  • Tumours were visualised with significantly higher SNR and CNR in dwMRI.
  • Median tumour volumes as measured by dwMRI (3.5 cm(3)) and mMRI (TrueFISP: 3.3 cm(3); FLASH: 3.3 cm(3); DESS: 3.2 cm(3)) were not significantly different and significantly correlated.
  • In conclusion, dwMRI allows tumour delineation with overall volume estimation comparable with mMRI approaches but slightly higher observer variability.
  • Thus, besides tumour outline, it may potentially supplement morphology-based therapy planning and monitoring with additional biological information.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Diffusion Magnetic Resonance Imaging / methods. Imaging, Three-Dimensional / methods. Lung Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Rats. Rats, Nude. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598006.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


64. Janssen MH, Aerts HJ, Kierkels RG, Backes WH, Ollers MC, Buijsen J, Lambin P, Lammering G: Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol; 2010 Feb;94(2):156-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings.
  • PURPOSE: The purpose of this study was to investigate perfusion of rectal tumors and to determine early responses to short-course hypofractionated radiotherapy (RT).
  • Contrast-enhancement was measured in tumor and muscle tissues and in the external iliac artery.
  • Perfusion differences between tumor and normal tissue and changes of the pharmacokinetic parameters between both scans were evaluated.
  • RESULTS: The median tumors K(trans) values increased significantly from the pre-scan (0.36+/-0.11 (min(-1))) to the post-scan (0.44+/-0.13 (min(-1))) (p<0.001).
  • Also, histogram analysis showed a shift of tumor voxels from lower K(trans) values towards higher K(trans) values.
  • Furthermore, the median K(trans) values were significantly higher for tumor than for muscle tissue on both the pre-scan (0.10+/-0.05 (min(-1)), p<0.001) and the post-scan (0.10+/-0.04 (min(-1)), p<0.001).
  • In contrast, no differences between tumor and muscle tissues were found for v(e) and v(p).
  • CONCLUSIONS: Hypofractionated radiotherapy of rectal cancer leads to an increased tumor perfusion as reflected by an elevated K(trans), possibly improving the bioavailability of cytotoxic agents in rectal tumors, often administered early after radiotherapy treatment.
  • [MeSH-major] Rectal Neoplasms / blood supply. Rectal Neoplasms / radiography. Rectal Neoplasms / radiotherapy. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media / pharmacokinetics. Dose Fractionation. Female. Fluorodeoxyglucose F18 / pharmacokinetics. Humans. Imaging, Three-Dimensional. Iohexol / analogs & derivatives. Iohexol / pharmacokinetics. Male. Neoplasm Staging. Radiopharmaceuticals / pharmacokinetics. Radiotherapy Dosage. Statistics, Nonparametric. Tomography, Emission-Computed

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20080311.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 182ECH14UH / iobitridol; 4419T9MX03 / Iohexol
  •  go-up   go-down


65. Kim YR, Yudina A, Figueiredo J, Reichardt W, Hu-Lowe D, Petrovsky A, Kang HW, Torres D, Mahmood U, Weissleder R, Bogdanov AA Jr: Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. Cancer Res; 2005 Oct 15;65(20):9253-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor.
  • Antiangiogenesis is emerging as efficient strategy for targeting and potentially eliminating neoplastic tumor vessels.
  • The main goal of this study was to establish whether absolute tumor blood volume (V(b)) change could be used as an early predictor of antiangiogenesis in ectopic and orthotopic colon carcinomas.
  • To assess therapy-induced changes of V(b), we did comparative analysis of signal intensities in tumors and muscle using steady-state magnetic resonance imaging (MRI) assisted with an intravascular paramagnetic contrast agent [gadolinium-labeled protected graft copolymer (PGC-Gd)].
  • Athymic mice with implanted human MV522 tumors were treated with vascular endothelial growth factor type 2 receptor tyrosine kinase inhibitor (VEGFR2-TKI) that has been shown to inhibit VEGFR2 phosphorylation and tumor growth in vivo.
  • The measured V(b) in ectopic tumors was 2.5 +/- 1.5% of total tissue volume 1 week after the implantation (n = 8).
  • In orthotopic tumors, the measured V(b) was initially higher (11.9 +/- 2.0%); however, VEGFR2-TKI treatment also resulted in a statistically significant decrease of V(b).
  • The absolute V(b) was not affected in the muscle as a result of treatments.
  • [MeSH-major] Adenocarcinoma / blood supply. Colonic Neoplasms / blood supply. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Erythrocyte Volume. Humans. Indazoles / pharmacology. Magnetic Resonance Angiography. Mice. Mice, Nude. Neovascularization, Pathologic / blood. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / enzymology. Neovascularization, Pathologic / radionuclide imaging. Phosphorylation. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors. Vascular Endothelial Growth Factor Receptor-2 / metabolism. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16230386.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P50CA86355-01; United States / NCI NIH HHS / CA / 5R01 CA74424-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AG 013925; 0 / Indazoles; 0 / Protein Kinase Inhibitors; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


66. Lee CM, Jeong HJ, Cheong SJ, Kim EM, Kim DW, Lim ST, Sohn MH: Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin. Pharm Res; 2010 Apr;27(4):712-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor-to-muscle ratios of C- and BC-NAHis-GC nanoparticles were 2.26 +/- 0.66 and 5.37 +/- 0.43, respectively.
  • The tumor accumulation of BC-NAHis-GC nanoparticles was clearly reduced by co-injection of BBN.
  • CONCLUSION: These results demonstrate that the BBN conjugation to NAHis-GC nanoparticles improves their tumor accumulation in PC3-bearing mice in comparison to nanoparticles without BBN, suggesting that BC-NAHis-GC nanoparticles may be useful for prostate cancer imaging.
  • [MeSH-major] Bombesin. Chitosan / chemistry. Nanoparticles. Neurotransmitter Agents. Prostatic Neoplasms / diagnosis. Receptors, Bombesin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Fluorescence. Magnetics. Male. Mice. Mice, Nude

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pharm. 2009 Apr 17;371(1-2):163-9 [19138733.001]
  • [Cites] Biomaterials. 2006 Jan;27(1):119-26 [16023198.001]
  • [Cites] J Control Release. 2009 Dec 16;140(3):210-7 [19560497.001]
  • [Cites] Methods. 2009 Jun;48(2):200-4 [19398012.001]
  • [Cites] J Control Release. 2006 Sep 28;115(1):37-45 [16935380.001]
  • [Cites] Small. 2008 Mar;4(3):372-9 [18232053.001]
  • [Cites] J Control Release. 2009 Sep 1;138(2):177-84 [19446585.001]
  • [Cites] Q J Nucl Med. 2000 Sep;44(3):208-23 [11105586.001]
  • [Cites] Nano Lett. 2006 Nov;6(11):2427-30 [17090068.001]
  • [Cites] Cancer. 1997 Dec 15;80(12 Suppl):2354-9 [9406683.001]
  • [Cites] J Pharm Pharmacol. 2009 Jun;61(6):713-9 [19505361.001]
  • [Cites] Bioorg Med Chem. 2009 Jul 15;17(14):4888-93 [19541487.001]
  • [Cites] Curr Pharm Des. 2008;14 (28):3033-47 [18991717.001]
  • [Cites] J Control Release. 2008 Oct 21;131(2):150-7 [18706946.001]
  • [Cites] Biomaterials. 2007 Feb;28(6):1236-47 [17126900.001]
  • [Cites] Biomaterials. 2008 Apr;29(12 ):1920-30 [18289669.001]
  • [Cites] J Control Release. 2006 Mar 10;111(1-2):228-34 [16458988.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(5):872-97 [19142939.001]
  • [Cites] J Control Release. 2004 Mar 24;95(3):579-88 [15023468.001]
  • [Cites] Radiology. 2009 Jul;252(1):101-8 [19561252.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Apr;19(2):219-29 [15186603.001]
  • [Cites] Nucl Med Commun. 2001 Jan;22(1):5-15 [11233552.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2286-91 [18381435.001]
  • [Cites] Biomaterials. 2009 May;30(15):2929-39 [19254811.001]
  • [Cites] J Control Release. 2008 Jun 24;128(3):217-23 [18457896.001]
  • [Cites] J Control Release. 2008 May 8;127(3):208-18 [18336946.001]
  • [Cites] Int J Pharm. 2009 May 8;372(1-2):169-76 [19429277.001]
  • [Cites] Nat Nanotechnol. 2009 Jul;4(7):457-63 [19581900.001]
  • [Cites] J Control Release. 2008 Apr 7;127(1):41-9 [18234388.001]
  • [Cites] J Control Release. 2007 Oct 8;122(3):305-14 [17643545.001]
  • [Cites] Arch Pharm Res. 2008 Jul;31(7):918-23 [18704336.001]
  • [Cites] J Control Release. 2008 May 22;128(1):23-31 [18374444.001]
  • [Cites] J Nucl Med. 2009 Sep;50(9):1387-90 [19690043.001]
  • (PMID = 20182773.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neurotransmitter Agents; 0 / Receptors, Bombesin; 0 / glycol-chitosan; 9012-76-4 / Chitosan; PX9AZU7QPK / Bombesin
  •  go-up   go-down


67. Svensson J, Johansson A, Gräfe S, Gitter B, Trebst T, Bendsoe N, Andersson-Engels S, Svanberg K: Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model. Photochem Photobiol; 2007 Sep-Oct;83(5):1211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model.
  • Treatment protocols for Temoporfin-mediated photodynamic therapy often rely on drug-light intervals of several days in order for the photosensitizer to accumulate within the target tissue, though tumor selectivity is limited.
  • Here, the mTHPC localization was studied at 2-8 h following systemic administration of a liposomal Temoporfin formulation (0.15 mg kg(-1) b.w.) in HT29 human colon adenocarcinoma in NMRI nu/nu mice.
  • Photosensitizer distribution within tumor and internal organs was investigated by means of high performance liquid chromatography following chemical extraction, as well as in situ fluorescence imaging and point-monitoring fluorescence spectroscopy.
  • For tumor tissue, the Temoporfin concentrations at 4 h (0.16+/-0.024 ng mg(-1)) and 8 h (0.18+/-0.064 ng mg(-1)) were significantly higher than at 2 h (0.08+/-0.026 ng mg(-1)).
  • The average tumor-to-muscle and the tumor-to-skin selectivity were 6.6 and 2, respectively, and did not vary significantly with time after photosensitizer injection.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Mesoporphyrins / administration & dosage. Photosensitizing Agents / administration & dosage
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Disease Models, Animal. HT29 Cells. Humans. Liposomes. Mice. Neoplasm Transplantation. Photochemotherapy. Spectrometry, Fluorescence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17880517.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Liposomes; 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


68. Roeb W, Boyer A, Cavenee WK, Arden KC: Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle; 2008 Apr 1;7(7):837-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The t(2;13) translocation is characteristic of the pediatric muscle tumor, alveolar rhabdomyosarcoma, and produces the chimeric transcription factor, PAX3-FOXO1, that contains the DNA binding elements of PAX3 and the transcriptional activation domain of FOXO1.
  • Experiments designed to determine how PAX3-FOXO1 expression contributes to the development of muscle cell-derived tumors resulted in the discovery that the fusion protein misregulates gene expression and interrupts myogenic differentiation through a unique gain of function mechanism.
  • These results yield new insight into how tumor-associated genetic alterations increase the likelihood of cancer formation and may lead to new therapeutic approaches.
  • [MeSH-major] Cell Differentiation / physiology. Early Growth Response Protein 1 / metabolism. Forkhead Transcription Factors / metabolism. Gene Expression Regulation, Neoplastic / physiology. Paired Box Transcription Factors / metabolism. Rhabdomyosarcoma, Alveolar / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Cycle. 2008 Oct;7(19):3106
  • (PMID = 18414034.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Early Growth Response Protein 1; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


69. Douma K, Oostendorp M, Slaaf DW, Post MJ, Backes WH, van Zandvoort MA: Evaluation of magnetic resonance vessel size imaging by two-photon laser scanning microscopy. Magn Reson Med; 2010 Apr;63(4):930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MR vessel size imaging (MR-VSI) is increasingly applied to noninvasively assess microvascular properties of tumors and to evaluate tumor response to antiangiogenic treatment.
  • MR-VSI provides measures for the microvessel radius and fractional blood volume of tumor tissue.
  • Therefore, three-dimensional two-photon laser scanning microscopy (TPLSM) was performed to assess microvascular radius and fractional vessel volume in tumor and muscle tissue.
  • TPLSM data displayed a mazelike architecture of the tumor microvasculature and mainly parallel oriented muscle microvessels.
  • For both MR-VSI and TPLSM, a larger vessel radius and fractional blood volume were found in the tumor rim than in the core.
  • The microvessel radius was approximately six times larger in tumor and muscle for MR-VSI than for TPLSM.
  • The tumor blood volume was 4-fold lower with MR-VSI than with TPLSM, whereas muscle blood volume was comparable for both techniques.
  • Differences between the tumor rim, core, and muscle tissue showed similar trends for both MR-VSI and TPLSM parameters.
  • [MeSH-major] Adenocarcinoma / pathology. Blood Volume Determination / methods. Colorectal Neoplasms / pathology. Magnetic Resonance Imaging / methods. Microscopy, Confocal / methods. Neovascularization, Pathologic / diagnosis
  • [MeSH-minor] Algorithms. Animals. Contrast Media. Dextrans. Ferrosoferric Oxide. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetite Nanoparticles. Male. Mice. Microcirculation. Muscle, Skeletal / blood supply. Photons. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373394.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / ferumoxtran-10; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


70. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, Senekowitsch-Schmidtke R, zum Büschenfelde CM, Peschel C, Schwaiger M, Dechow T, Buck AK: Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol; 2008 Nov-Dec;10(6):349-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Tumor growth in untreated animals was significantly higher than in treated animals.
  • In FLT-PET scans, these observations correlated with a significant decrease of tumor-to-background ratio in the therapy group already at day 1.
  • Likewise, median tumor-to-muscle ratio of FLT uptake already declined at day 1.
  • A significant decrease of FLT uptake but not tumor growth was detectable already 24 h after therapy and correlated with reduced proliferation and induction of apoptosis.
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / therapeutic use. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dideoxynucleosides. Doxorubicin / therapeutic use. Female. Humans. Mice. Mice, SCID. Neoplasm Transplantation. Positron-Emission Tomography. Radiopharmaceuticals. Transplantation, Heterologous

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Blood. 1999 Jul 15;94(2):429-33 [10397709.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):257-63 [15791434.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Apr;36(4):808-18 [1503443.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Nov;34(11):1775-82 [17541585.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1174-81 [12192562.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] Radiographics. 2005 Jan-Feb;25(1):191-207 [15653595.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10 (5):1685-90 [15014020.001]
  • [Cites] J Neurochem. 2000 Aug;75(2):532-9 [10899928.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47 [17333178.001]
  • [Cites] Cancer Res. 2003 May 15;63(10 ):2681-7 [12750297.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):571-8 [17242397.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1688-98 [12468521.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12 (15):4590-7 [16899606.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):412-9 [16404598.001]
  • [Cites] Cancer Res. 1976 Aug;36(8):2891-5 [1277199.001]
  • [Cites] J Biol Chem. 1988 Jun 15;263(17):8350-8 [3372530.001]
  • [Cites] J Nucl Med. 1988 Oct;29(10 ):1633-7 [3262725.001]
  • [Cites] Blood. 2001 Apr 1;97(7):1999-2007 [11264164.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Oct;303(1):124-31 [12235242.001]
  • [Cites] Ann Oncol. 2001 May;12 (5):719-22 [11432634.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12 ):3552-8 [17575218.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):878-83 [17195074.001]
  • [Cites] J Nucl Med. 2007 May;48(5):726-35 [17475960.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):11055-61 [17108145.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):746-53 [17454633.001]
  • [Cites] Adv Enzyme Regul. 1994;34:13-25 [7942271.001]
  • [Cites] Cancer Res. 2005 May 15;65(10 ):4202-10 [15899811.001]
  • [Cites] J Clin Oncol. 1988 Dec;6(12 ):1832-7 [3199167.001]
  • [Cites] J Nucl Med. 1998 Oct;39(10 ):1757-62 [9776283.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4 [14991243.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • (PMID = 18704591.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 80168379AG / Doxorubicin; PG53R0DWDQ / alovudine
  •  go-up   go-down


71. Mellon EA, Lee SC, Pickup S, Kim S, Goldstein SC, Floyd TF, Poptani H, Delikatny EJ, Reddy R, Glickson JD: Detection of lactate with a hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQC-CSI) on a clinical MRI scanner: Application to tumors and muscle ischemia. Magn Reson Med; 2009 Dec;62(6):1404-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of lactate with a hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQC-CSI) on a clinical MRI scanner: Application to tumors and muscle ischemia.
  • To demonstrate clinical feasibility, a 5-min lactate scan of a patient with a non-Hodgkin's lymphoma in the superficial thigh is reported.
  • The elevated lactate signal coincides with the T(2)-weighted image of this tumor.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • [Cites] Radiology. 2003 Nov;229(2):366-74 [14512508.001]
  • [Cites] J Exp Biol. 2003 Sep;206(Pt 17):3043-52 [12878672.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Sep;287(3):R502-16 [15308499.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1083-100 [15488559.001]
  • [Cites] Am J Physiol. 1986 Feb;250(2 Pt 2):H213-20 [3946620.001]
  • [Cites] Eur J Clin Invest. 1985 Dec;15(6):382-8 [3938408.001]
  • [Cites] J Comput Assist Tomogr. 1988 Nov-Dec;12(6):1026-30 [3183105.001]
  • [Cites] Magn Reson Med. 1988 Jul;7(3):364-70 [3205153.001]
  • [Cites] Radiology. 1990 May;175(2):381-5 [2326464.001]
  • [Cites] Magn Reson Med. 1990 Nov;16(2):192-225 [2266841.001]
  • [Cites] NMR Biomed. 1992 Mar-Apr;5(2):75-86 [1622767.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):681-6 [8489495.001]
  • [Cites] J Magn Reson B. 1994 May;104(1):1-10 [8025810.001]
  • [Cites] J Magn Reson B. 1995 Mar;106(3):203-11 [7719620.001]
  • [Cites] J Clin Invest. 1996 Jul 15;98(2):244-50 [8755630.001]
  • [Cites] Magn Reson Med. 1996 Sep;36(3):487-90 [8875423.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):635-9 [8948348.001]
  • [Cites] Magn Reson Med. 1997 May;37(5):644-50 [9126937.001]
  • [Cites] Invest Radiol. 1997 Nov;32(11):651-9 [9387051.001]
  • [Cites] NMR Biomed. 1997 Dec;10(8):435-44 [9542740.001]
  • [Cites] Magn Reson Med. 1999 Jun;41(6):1145-51 [10371446.001]
  • [Cites] J Neurol Sci. 2005 Mar 15;229-230:131-9 [15760631.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):760-9 [15814918.001]
  • [Cites] J Vasc Surg. 2006 May;43(5):978-86 [16678693.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1079-85 [17969083.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2129-36 [18310508.001]
  • [Cites] NMR Biomed. 2008 Aug;21(7):723-33 [18384181.001]
  • [Cites] J Magn Reson Imaging. 2008 Aug;28(2):445-52 [18666182.001]
  • [Cites] Magn Reson Med. 2008 Aug;60(2):299-305 [18666110.001]
  • [Cites] NMR Biomed. 2009 Apr;22(3):259-65 [19040203.001]
  • [Cites] J Vasc Surg. 2000 May;31(5):944-52 [10805885.001]
  • [Cites] J Magn Reson. 2001 May;150(1):17-25 [11330978.001]
  • [Cites] Annu Rev Med. 2002;53:89-112 [11818465.001]
  • [Cites] NMR Biomed. 2003 Apr;16(2):102-11 [12730951.001]
  • [Cites] Acad Radiol. 2004 Apr;11(4):368-76 [15109009.001]
  • (PMID = 19785016.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS059116-01A1; United States / NCI NIH HHS / CA / R01-CA102756; United States / NCRR NIH HHS / RR / RR002305-24; United States / NCI NIH HHS / CA / CA083105-01; United States / NCRR NIH HHS / RR / P41 RR002305-23; United States / NCI NIH HHS / CA / R01 CA101700-03; United States / NCRR NIH HHS / RR / P41 RR002305-25S1; United States / NCI NIH HHS / CA / CA102756-01A1; United States / NCRR NIH HHS / RR / P41 RR002305-26; United States / NCI NIH HHS / CA / CA101700-03; United States / NCI NIH HHS / CA / R01 CA101700-02; United States / NCI NIH HHS / CA / CA101700-01A1; United States / NCI NIH HHS / CA / R01CA118559; United States / NCI NIH HHS / CA / CA101700-05A2; United States / NCI NIH HHS / CA / R01 CA101700-01A1; United States / NINDS NIH HHS / NS / F30NS059116; United States / NCI NIH HHS / CA / R01 CA101700; United States / NCI NIH HHS / CA / R01 CA102756-01A1; United States / NCI NIH HHS / CA / CA101700-06; United States / NCI NIH HHS / CA / CA101700-04; United States / NCI NIH HHS / CA / R01 CA101700-04; United States / NCI NIH HHS / CA / CA101700-07; United States / NCI NIH HHS / CA / U24 CA083105; United States / NCI NIH HHS / CA / R01CA101700; United States / NCI NIH HHS / CA / R01 CA101700-07; United States / NCI NIH HHS / CA / R01 CA118559-01A1; United States / NINDS NIH HHS / NS / F30 NS059116; United States / NCRR NIH HHS / RR / RR02305; United States / NCI NIH HHS / CA / R24 CA083105-01; United States / NCI NIH HHS / CA / R01 CA118559; United States / NCI NIH HHS / CA / CA118559-01A1; United States / NCI NIH HHS / CA / R24 CA083105; United States / NCI NIH HHS / CA / R01 CA101700-05A2; United States / NCI NIH HHS / CA / CA101700-02; United States / NCI NIH HHS / CA / R01 CA101700-06; United States / NINDS NIH HHS / NS / F30 NS059116-01A1; United States / NCRR NIH HHS / RR / RR002305-23; United States / NCRR NIH HHS / RR / P41 RR002305-24; United States / NCRR NIH HHS / RR / P41 RR002305; United States / NCRR NIH HHS / RR / P41 RR002305-27; United States / NCI NIH HHS / CA / R01 CA102756; United States / NCI NIH HHS / CA / 2U24CA083105; United States / NCRR NIH HHS / RR / P41 RR002305-25
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 33X04XA5AT / Lactic Acid
  • [Other-IDs] NLM/ NIHMS259859; NLM/ PMC3021464
  •  go-up   go-down


72. Bodner-Adler B, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K: Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol; 2005 Jan;96(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
  • OBJECTIVE: The loss of cell cycle control is a critical step in the development of neoplasia.
  • The p16 protein has been identified as a tumor suppressor protein, which binds specifically to the cyclin-dependent kinase CDK-4, inhibiting the catalytic activity of the CDK4-cyclin D complex, and thereby acts as a negative cell cycle regulator.
  • In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS).
  • METHODS: P16 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 patients with STUMP, and in 21 patients with LMS.
  • No statistically significant correlation between p16 expression and clinical stage, age, vascular space involvement, and recurrence disease could be found in patients with LMS (P > 0.05).
  • Furthermore, p16 might be a useful immunohistochemical marker, which could help to distinguish cases of smooth muscle tumors in which histologic features are ambiguous or borderline, but the use of p16 in a diagnostic setting should await further clinical studies and clarification of the mechanisms.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Smooth Muscle Tumor / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Leiomyoma / metabolism. Leiomyoma / pathology. Leiomyoma / therapy. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Leiomyosarcoma / therapy. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589581.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


73. Brunstein F, Hoving S, aan de Wiel-Ambagtsheer G, de Bruijn EA, Guetens G, Eggermont AM, ten Hagen TL: Decreased response rates by the combination of histamine and IL-2 in melphalan-based isolated limb perfusion. Cancer Immunol Immunother; 2007 Apr;56(4):573-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histamine (Hi) combined to melphalan in a rat experimental model of isolated limb perfusion (ILP) for lower limb soft tissue sarcoma, resulted in overall response rates (OR) of 66%.
  • In systemic immunotherapy, the combination of IL-2 and Hi has been used for solid tumor treatment based on immunomodulatory effects.
  • Melphalan uptake by tumor and muscle were measured.
  • Histology of tumors demonstrated partial loss of Hi-induced hemorrhagic effect when IL-2 was present.
  • Melphalan accumulation in the tumor when both Hi and IL-2 were added (3.1-fold) was very similar to accumulation with Hi only (2.8-fold), or IL-2 only (3.5-fold) combined to melphalan.

  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896966.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Histamine Agents; 0 / Interleukin-2; 0 / Recombinant Proteins; 820484N8I3 / Histamine; Q41OR9510P / Melphalan
  •  go-up   go-down


74. Zhang X, Rong TH, Wu QL, Fu JH, Long H, Zhang LJ, Ma GW, Su XD, Li XD, Wang DF, Hu Y, Yang H: [Differential diagnosis and treatment of esophageal stromal tumors and smooth muscle tumors]. Ai Zheng; 2006 Jul;25(7):901-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment of esophageal stromal tumors and smooth muscle tumors].
  • BACKGROUND & OBJECTIVE: Esophageal stromal tumors and smooth muscle tumors are not easy to be distinguished in clinic though they have different pathologic features.
  • This study was to compare the clinicopathologic features of esophageal stromal tumors and smooth muscle tumors, and discuss their treatments.
  • METHODS: The expression of CD117 and CD34 in 16 specimens of primarily diagnosed esophageal leiomyoma, 4 specimens of esophageal leiomyosarcoma, and 1 specimen of stromal tumor was detected by immunohistochemistry.
  • RESULTS: Of the 16 cases of primarily diagnosed esophageal leiomyoma, 5 were CD117(+) and finally diagnosed as non-high aggressive fatal stromal tumor according to the assessment criteria of stromal tumors; 11 were CD117(-).
  • The stromal tumor was CD117(+) and CD34(+), and diagnosed as high aggressive fatal stromal tumor.
  • There was no obvious difference in clinicopathologic manifestations, treatment and prognosis between esophageal non-high aggressive fatal stromal tumor and leiomyoma, and between esophageal high aggressive fatal stromal tumor and leiomyosarcoma.
  • CONCLUSIONS: Esophageal stromal tumors and smooth muscle tumors can not be distinguished with clinicopathologic exhibitions.
  • Lumpectomy or esophageal partial resection is enough for esophageal non-high aggressive fatal stromal tumor and leiomyoma.
  • Esophageal partial resection is necessary for esophageal high aggressive fatal stromal tumor and leiomyosarcoma.
  • [MeSH-major] Esophageal Neoplasms / pathology. Gastrointestinal Stromal Tumors / pathology. Leiomyoma / pathology. Leiomyosarcoma / pathology. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Antigens, CD34 / metabolism. Diagnosis, Differential. Esophagectomy / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neurofilament Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831287.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / Neurofilament Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


75. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • Tumor hypoxia reduces the effectiveness of both radiation therapy and chemotherapy and is a well-known risk factor for tumor radioresistence.
  • Pretreatment tumor size and stage were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
  • The primary tumor was imaged by positron emission tomography with (60)Cu-ATSM, and accumulation of the tracer was measured semiquantitatively by determining the tumor-to-muscle activity ratio.
  • Proctectomy was performed six to eight weeks after neoadjuvant chemoradiotherapy and the tumor submitted to pathology for size measurement and staging.
  • Tumor-to-muscle activity ratios were compared with tumor (18)F-fluorodeoxyglucose uptake, tumor response to neoadjuvant chemoradiotherapy, and with patient survival.
  • RESULTS: Nineteen patients were enrolled in the study, two of whom were excluded from final analysis (1 death during neoadjuvant chemoradiotherapy and 1 tumor perforation during neoadjuvant chemoradiotherapy requiring emergent surgery).
  • Of the 17 remaining patients, 14 had a reduction in tumor size and 13 were downstaged.
  • The median tumor-to-muscle activity ratio of 2.6 discriminated those with worse prognosis from those with better prognosis.
  • Both overall and progression-free survivals were worse with hypoxic tumors (tumor-to-muscle activity ratio >2.6) than with nonhypoxic tumors (tumor-to-muscle activity ratio <or=2.6; both P < 0.05).
  • In addition, 2 of the 3 tumors with no change in size had tumor-to-muscle activity ratios >2.6 (positive predictive value 66 percent), whereas 6 of 14 with decreased size had tumor-to-muscle activity ratios >2.6 (negative predictive value 57 percent).
  • Three of the 4 tumors not downstaged had tumor-to-muscle activity ratios >2.6 (positive predictive value 75 percent), whereas 5 of 13 downstaged tumors had tumor-to-muscle activity ratios >2.6 (negative predictive value 62 percent).
  • The mean tumor-to-muscle activity ratio for downstaged tumors (2.2) was significantly lower than that of nondownstaged tumors (3.3) (P = 0.03).
  • The difference in mean tumor-to-muscle activity ratio between downsized (2.3) and nondownsized (2.9) tumors did not reach statistical significance (P = 0.36).
  • Tumor (18)F-fluorodeoxyglucose uptake (n = 11) did not correlate with (60)Cu-ATSM uptake (r = 0.4; P = 0.9) and there was no significant difference in mean tumor (18)F-fluorodeoxyglucose uptake between patients with hypoxic tumors and those with normoxic tumors (P = 0.3).
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones
  • [MeSH-minor] Adult. Aged. Cell Hypoxia. Cohort Studies. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Pilot Projects. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


76. Mukaisho K, Miwa K, Totsuka Y, Shimomura A, Sugihara H, Wakabayashi K, Hattori T: Induction of gastric GIST in rat and establishment of GIST cell line. Cancer Lett; 2006 Jan 18;231(2):295-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Continuous administration of the direct-reacting carcinogen N-methyl-N'-nitro-N-nitrosoguanidine reportedly produces not only adenocarcinoma in rats, but also mesenchymal tumors.
  • A large number of tumors diagnosed as gastrointestinal smooth muscle tumors actually represent gastrointestinal stromal tumors (GISTs) in human cases.
  • We have induced mesenchymal tumors by duodenal reflux in rats.
  • To clarify the differentiation of these mesenchymal tumors, immunohistochemical investigations were undertaken.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Mesenchymoma / pathology
  • [MeSH-minor] Animals. Antigens, CD34 / metabolism. Antineoplastic Agents / pharmacology. Benzamides. Cell Line, Tumor. Cell Proliferation / drug effects. Duodenogastric Reflux. Imatinib Mesylate. In Vitro Techniques. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Piperazines / pharmacology. Proto-Oncogene Proteins c-kit / metabolism. Pyrimidines / pharmacology. Rats. Rats, Wistar

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882927.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


77. Murray SK, Clement PB, Young RH: Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol; 2005 Feb;29(2):157-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms.
  • These features, particularly when prominent, produced an appearance strikingly different from that of conventional EC, sometimes resulting in problems in differential diagnosis, especially with a malignant mullerian mixed tumor (carcinosarcoma).
  • On microscopic examination, typical EC, which accounted for 10% to 90% of the tumor, was admixed in 90% of cases with cords of epithelioid or spindle cells within a hyalinized stroma.
  • In 3 cases, the tumor contained cords of cells without a hyalinized stroma.
  • Seventy percent of the tumors exhibited squamous differentiation, and in 50% of the tumors there was a background of endometrial hyperplasia.
  • Two thirds of the tumors were grade 2 and the remainder were grade 1.
  • Vascular space invasion was identified in seven tumors.
  • Muscle markers (desmin, actin), CD10, and inhibin were negative in the latter.
  • Eighty-three percent of the patients were alive with no evidence of disease on follow-up (range, 2-115 months; mean, 34.4 months).
  • The clinical features, including a typically low stage and generally good prognosis, and histologic findings are different from those of malignant mullerian mixed tumors that are characterized by both high-grade carcinomatous and sarcomatous components and an aggressive clinical course.
  • Confusion with other neoplasms, particularly those with sex cord-like growth, such as uterine tumors resembling ovarian sex cord tumors and epithelioid smooth muscle tumors, may also arise.
  • We refer to tumors with the features described herein as "corded and hyalinized endometrioid carcinomas," a designation that reflects their two most striking and consistent features.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinosarcoma / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644772.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Okuma T, Matsuoka T, Okamura T, Wada Y, Yamamoto A, Oyama Y, Koyama K, Nakamura K, Watanabe Y, Inoue Y: 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med; 2006 Aug;47(8):1351-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits.
  • The primary goals of this study were to investigate the behavior of normal lung tissues after radiofrequency ablation (RFA) and to determine the suitability of 18F-FDG PET, using a dedicated small-animal scanner, for monitoring the early therapeutic effects of RFA on VX2 lung tumors (VX2s) in rabbits.
  • The mean early- (40-60 min after injection) and delayed (100-120 min)-phase ablated lesion-to-muscle ratios were, respectively, 2.9 +/- 1.0 and 3.3 +/- 0.8 (1 d), 4.1 +/- 0.6 and 5.2 +/- 0.9 (1 wk), 4.1 +/- 1.0 and 5.3 +/- 1.5 (2 wk), 3.1 +/- 0.5 and 3.6 +/- 1.1 (4 wk), and 1.8 +/- 0.1 and 2.3 +/- 0.1 (8 wk).
  • VX2s showed mean tumor-to-muscle ratios of 6.6 +/- 2.1 and 8.6 +/- 3.3 at the early and delayed phases, respectively.
  • For ablated tumors, the respective ratios were 0.8 +/- 0.4 and 1.1 +/- 0.7 (1 d) and 1.2 +/- 0.5 and 1.5 +/- 0.7 (1 wk).
  • These values were significantly lower than those for nonablated tumors (P < 0.001).
  • Histopathologic examination confirmed the absence of viable tumors.
  • 18F-FDG accumulation around ablated tumors reflected thermally damaged normal tissues and was significantly lower than that of control VX2s (P < 0.01).
  • Delayed-phase images seem to better distinguish tumor from inflammation than do early-phase images.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / therapy. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Animals. Carcinoma / pathology. Catheter Ablation. Disease Models, Animal. Humans. Inflammation. Lung / pathology. Neoplasm Transplantation. Rabbits. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Nucl Med. 2006 Aug;47(8):1235-7 [16882998.001]
  • (PMID = 16883016.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


79. Wang Y, Zhu H, Zhao HP, Hei Y, Xiao LH: [Diagnosis and management of the tumors of extraocular muscles]. Zhonghua Yan Ke Za Zhi; 2009 Jan;45(1):56-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and management of the tumors of extraocular muscles].
  • OBJECTIVE: To evaluate the spectrum, clinical features, diagnostic methods and treatment of the tumors of extraocular muscles.
  • METHODS: In a retrospective case series study,the records of 11 consecutive cases with tumors of the extraocular muscles confirmed by pathologic examination were analyzed with special attention to the clinical manifestations, imaging findings, treatment and prognosis.
  • RESULTS: There were fibromatosis in 3 cases, intermuscular hemangioma and granular cell tumor both in 2 cases, inflammatory myofibroblastic tumor, rhabdomyosarcoma, T cell lymphoma and metastatic adenocarcinoma all in 1 case.
  • In respect to images of computed tomography or magnetic resonance imaging, the configuration of the extraocular muscles with tumors demonstrated 3 patterns, fusiform, globular and irregular.
  • The tumors that involved inferior, medial and lateral rectus muscles, and inferior oblique muscle, their maximal diameters all exceeded 1 cm.
  • Depending on the involved muscles, different operative approaches were applied.
  • The choice of treatments was determined by the pathology of the tumors.
  • CONCLUSIONS: The spectrum, clinical features and imaging findings of the tumors of extraocular muscles are unique.
  • The prognosis is correlated with treatments and the characteristic of tumors.
  • [MeSH-major] Eye Neoplasms / diagnosis. Eye Neoplasms / therapy. Neoplasms, Muscle Tissue / diagnosis. Neoplasms, Muscle Tissue / therapy. Oculomotor Muscles

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484932.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH: Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med; 2006 Jan;47(1):150-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation.
  • Novel radiopharmaceuticals for the detection of tumors and their metastases may be of clinical interest if they are more tumor selective than (18)F-FDG.
  • The model consisted of male Wistar rats that bore tumors (C6 rat glioma in the right shoulder) and also had sterile inflammation in the left calf muscle (induced by injection of 0.1 mL of turpentine).
  • RESULTS: (18)F-FDG showed the highest tumor-to-muscle ratio of all radiopharmaceuticals (13.2 +/- 3.0, mean +/- SD), followed at a large distance by the sigma-1 ligand (11)C-SA4503 (5.1 +/- 1.7), (18)F-FLT (3.8 +/- 1.3), the non-subtype-selective sigma-ligand (18)F-FE-SA5845 (3.3 +/- 1.5), (11)C-choline (3.1 +/- 0.4), and (11)C-methionine (2.8 +/- 0.3).
  • sigma-Ligands and (18)F-FLT were relatively tumor selective ((18)F-FE-SA5845, greater than 30-fold; (11)C-SA4503 and (18)F-FLT, greater than 10-fold).
  • The tumor selectivity of (11)C-methionine was only slightly better than that of (18)F-FDG. (11)C-Choline showed equal uptake in tumor and inflammation.
  • All tracers were avidly taken up by proliferative tissue (small intestine, bone marrow).
  • CONCLUSION: sigma-Ligands and (18)F-FLT were more tumor selective than (18)F-FDG, (11)C-choline, or (11)C-methionine in our animal model.
  • [MeSH-minor] Animals. Diagnosis, Differential. Male. Metabolic Clearance Rate. Organ Specificity. Radiopharmaceuticals / pharmacokinetics. Rats. Rats, Wistar. Reproducibility of Results. Sensitivity and Specificity. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16391199.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, sigma
  •  go-up   go-down


81. Kaneta T, Takai Y, Iwata R, Hakamatsuka T, Yasuda H, Nakayama K, Ishikawa Y, Watanuki S, Furumoto S, Funaki Y, Nakata E, Jingu K, Tsujitani M, Ito M, Fukuda H, Takahashi S, Yamada S: Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med; 2007 Feb;21(2):101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we analyzed dynamic whole-body imaging in healthy volunteers and dynamic tumor imaging in three patients with lung cancer.
  • Volunteers underwent dynamic whole-body scans just after injection of 18F-FRP170 for about 90 min, while the lung cancer patients underwent dynamic tumor imaging for about 60 or 120 min.
  • Regions of interest were placed over images of each organ or tumor to generate time-SUV curves.
  • The changes of tumor SUV, tumor/blood ratio, or tumor/muscle ratio about 30 min after injection or later were small.
  • The background activity above the diaphragm was very low, and patients with lung cancer showed clear tumor uptake of 18F-FRP170 early after injection.
  • [MeSH-major] Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. Nitroimidazoles / pharmacokinetics. Positron-Emission Tomography / methods. Whole Body Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Organ Specificity. Pilot Projects. Radiopharmaceuticals / pharmacokinetics. Reproducibility of Results. Sensitivity and Specificity. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17424976.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FRP-170; 0 / Nitroimidazoles; 0 / Radiopharmaceuticals
  •  go-up   go-down


82. Hamazawa Y, Koyama K, Okamura T, Wada Y, Wakasa T, Okuma T, Watanabe Y, Inoue Y: Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model. Ann Nucl Med; 2007 Jan;21(1):47-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model.
  • PURPOSE: We investigated the optimum time for the differentiation tumor from inflammation using dynamic FDG-microPET scans obtained by a MicroPET P4 scanner in animal models.
  • Five rabbits with 10 VX2 tumors were used as the tumor model.
  • For quantitative analysis, the inflammation-to-muscle (I/M) ratio and tumor-to-muscle (T/M) ratio were calculated after regions of interest were set in tumors and muscles referring to CT images and the time-I/M ratio and time-T/M ratio curves (TRCs) were prepared to show the change over time in these ratios.
  • The histological appearance of both inflammatory lesions and tumor lesions were examined and compared with the CT and FDG-microPET images.
  • RESULTS: In visual and quantitative analysis, All the I/M ratios and the T/M ratios increased over time except that Day 60 of Group 1 showed an almost flat curve.
  • For differentiating tumors from inflammatory lesions with the early image acquired at 40 min for dual-time imaging, the delayed image must be acquired 30 min after the early image, while imaging at 90 min or later after intravenous FDG injection was necessary in single-time-point imaging.
  • [MeSH-minor] Animals. Disease Models, Animal. Neoplasms, Experimental / pathology. Rabbits

  • Hazardous Substances Data Bank. TURPENTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373336.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8006-64-2 / Turpentine
  •  go-up   go-down


83. Ito M, Yang DJ, Mawlawi O, Mendez R, Oh CS, Azhdarinia A, Greenwell AC, Yu DF, Kim EE: PET and planar imaging of tumor hypoxia with labeled metronidazole. Acad Radiol; 2006 May;13(5):598-609
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and planar imaging of tumor hypoxia with labeled metronidazole.
  • RATIONALE AND OBJECTIVES: This study was aimed to develop 99mTc- and 68Ga-labeled metronidazole (MN) using ethylenedicysteine (EC) as a chelator and evaluate their potential use to assess tumor hypoxia.
  • In vitro cellular uptakes of 99mTc- and 68Ga-EC-MN were obtained in various types of tumor cells at 0.5-4 hours.
  • Tissue distribution and PET imaging of 99mTc and 68Ga-EC-MN were evaluated in breast tumor-bearing rats at 0.5-4 hours.
  • Tumor oxygen tension was measured using an oxygen probe.
  • In vivo biodistribution of 99mTc- and 68Ga-EC-MN in breast tumor-bearing rats showed increased tumor-to-blood and tumor-to-muscle count density ratios as a function of time.
  • Positron emission tomography images confirmed that the tumors could be visualized clearly with 68Ga-EC-MN.
  • Oxygen tension in tumor tissue was determined to be 6-10 mm Hg compared with 40-50 mm Hg in normal muscle tissue.
  • CONCLUSIONS: The results indicated that it is feasible to use 99mTc- and 68Ga-EC-MN for assessment of tumor hypoxia.
  • [MeSH-major] Lung Neoplasms / metabolism. Lung Neoplasms / radionuclide imaging. Metronidazole / analogs & derivatives. Organometallic Compounds / pharmacokinetics. Organotechnetium Compounds / pharmacokinetics. Oxygen / metabolism. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Cell Hypoxia. Cell Line, Tumor. Feasibility Studies. Female. Isotope Labeling / methods. Metabolic Clearance Rate. Organ Specificity. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Rats. Rats, Inbred F344. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • Hazardous Substances Data Bank. OXYGEN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627201.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / gallium-68-ethylenedicysteine-metronidazole; 0 / technetium 99m ethylenedicysteine-metronidazole; 140QMO216E / Metronidazole; S88TT14065 / Oxygen
  •  go-up   go-down


84. Farah-Klibi F, Ben Hamouda S, Ben Romdhane S, Sfar R, Koubaa A, Ben Jilani S, Zermani R: [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. J Gynecol Obstet Biol Reprod (Paris); 2008 Sep;37(5):457-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus].
  • [Transliterated title] Etude immunohistochimique des sarcomes du stroma endométrial et des tumeurs musculaires lisses de l'utérus.
  • OBJECTIVES: Positive and differential diagnoses of mesenchymal tumors of the uterus may be sometimes problematic.
  • The purpose of this study was to evaluate the utility of a panel of antibodies in this diagnosis.
  • It seems to have the best value in the diagnosis of mesenchymal tumors in association with desmin and h-caldesmon, specific markers of smooth-muscle differentiation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / diagnosis. Sarcoma, Endometrial Stromal / diagnosis
  • [MeSH-minor] Actins / analysis. Calmodulin-Binding Proteins / analysis. Desmin / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Leiomyoma / diagnosis. Leiomyosarcoma / diagnosis. Neprilysin / analysis. Retrospective Studies. Uterine Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565690.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calmodulin-Binding Proteins; 0 / Desmin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


85. Ou XH, Tan TZ, Li YC: [Preparation and biodistribution of VIP-125I-ASON]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Sep;36(5):713-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The iodination of a 15-base single-stranded antisense oligonucleotide (ASON) complementary to C-myc oncogene mRNA was carried out in the presence of TICl3.
  • The highest uptake of tumor tissue (5.89% ID/g at 2 h) was significantly higher than that in nude mice given unconjugated ASON (P < 0.05).
  • Tumor to blood ratios and tumor to muscle ratios were optimal at 4 h.
  • CONCLUSION: VIP-125I-ASON has desirable stability and higher uptake in tumor.
  • It may provide a new sensitive mean for diagnostic antisense imaging and radiotherapy of tumor in the future.
  • [MeSH-minor] Animals. Colonic Neoplasms / radionuclide imaging. Colonic Neoplasms / radiotherapy. Mice. Mice, Inbred BALB C. Mice, Nude. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235546.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Oligonucleotides, Antisense; 0 / Radiopharmaceuticals; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


86. Mallia MB, Mathur A, Subramanian S, Banerjee S, Sarma HD, Venkatesh M: A novel [99mTc[triple bond]N]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia. Bioorg Med Chem Lett; 2005 Jul 15;15(14):3398-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A xanthate derivative (L) at the pendant hydroxy group of metronidazole, a nitroimidazole known to possess affinity for hypoxic tumors, has been used as the carrier molecule for targeted delivery of the gamma-emitting radioisotope 99mTc to tumors.
  • Biodistribution studies carried out in Swiss mice bearing fibrosarcoma tumor showed selective accumulation of the injected activity in the tumor (1.44 +/- 0.26% per gram 1 h pi) with major clearance through hepatobiliary route.
  • The complex showed high tumor/muscle ratio (2.15 and 3.35 at 1 and 3 h post-injection, respectively) and tumor/blood ratio, which were comparable to hypoxia targeting agents 99mTc-BMS181321 and 99mTc-BRU59-21 reported earlier.
  • [MeSH-major] Hypoxia / diagnosis. Metronidazole. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Animals. Imidazoles / pharmacokinetics. Ligands. Mice. Molecular Structure. Neoplasm Transplantation. Neoplasms, Experimental / diagnostic imaging. Nitroimidazoles / pharmacokinetics. Radionuclide Imaging. Structure-Activity Relationship. Time Factors. Tissue Distribution

  • Hazardous Substances Data Bank. METRONIDAZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044527.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRU 59-21; 0 / Imidazoles; 0 / Ligands; 0 / Nitroimidazoles; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 140QMO216E / Metronidazole; 149447-21-2 / BMS 181321
  •  go-up   go-down


87. Luo Y, Pang H, Li S, Cao H, Peng Z, Fan C, Li S: Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther; 2009 Jul;8(14):1369-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Peroxiredoxin I (Prx I) is a member of the Peroxiredoxin family, which is overexpressed in many diverse tumor types and is an anti-apoptosis protein for tumor cell proliferation and survival.
  • The radiolocalization index (RI) of tumor/serum and tumor/muscle gradually increased, reaching its peak (4.06 +/- 0.13 and 5.17 +/- 0.97, respectively) at 48 h postadministration.
  • Single photon emission computed tomography (SPECT) imaging showed the radioactivity was aggregated in tumor locations and tumor imaging was clearly observed.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Neoplasm Proteins / antagonists & inhibitors. Peptide Library. Peroxiredoxins / antagonists & inhibitors. Radioimmunodetection. Single-Chain Antibodies / therapeutic use. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Animals. Antibody Affinity. Apoptosis / drug effects. Apoptosis / immunology. Breast Neoplasms / immunology. Breast Neoplasms / pathology. Bronchi / cytology. Bronchi / immunology. Drug Delivery Systems. Epithelial Cells / immunology. Genes, Immunoglobulin. Humans. Iodine Radioisotopes. Mice. Mice, Nude. Recombinant Proteins / immunology. Tissue Distribution. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556853.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Peptide Library; 0 / Recombinant Proteins; 0 / Single-Chain Antibodies; EC 1.11.1.15 / PRDX1 protein, human; EC 1.11.1.15 / Peroxiredoxins
  •  go-up   go-down


88. Cornfeld D, Israel G, Martel M, Weinreb J, Schwartz P, McCarthy S: MRI appearance of mesenchymal tumors of the uterus. Eur J Radiol; 2010 Apr;74(1):241-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearance of mesenchymal tumors of the uterus.
  • PURPOSE: Uterine leiomyomas are the most common uterine neoplasms.
  • Statistically, a uterine mass with unusual imaging features is more likely to represent a leiomyoma than other uncommon uterine mesenchymal neoplasms such as leiomyosarcoma or endometrial stromal tumors.
  • Four patients with uterine leiomyosarcoma, two with stromal tumors of uncertain malignant potential (STUMP), one with endometrial stromal sarcoma, and two with mixed endometrial stromal and smooth muscle tumors were included in the study.
  • RESULTS: None of the objective criteria were associated with the presence or absence of uterine mesenchymal neoplasm.
  • Reader gestalt was statistically associated with the presence of mesenchymal neoplasm for one of our readers (p=0.02) but not for the other (p=0.07).
  • CONCLUSION: We found poor accuracy for objective imaging criteria in distinguishing leiomyomas with atypical imaging features from more clinically significant uterine mesenchymal neoplasms.
  • [MeSH-major] Leiomyosarcoma / radiography. Rhabdomyosarcoma / radiography. Sarcoma, Endometrial Stromal / radiography. Uterine Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endometrial Neoplasms / radiography. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19349135.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


89. Solomon B, Binns D, Roselt P, Weibe LI, McArthur GA, Cullinane C, Hicks RJ: Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther; 2005 Sep;4(9):1417-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blockade of signaling through the epidermal growth factor receptor (EGFR) tyrosine kinase by inhibitors such as gefitinib (Iressa) can inhibit tumor angiogenesis and enhance responses to ionizing radiation.
  • Serial noninvasive PET imaging of A431 xenografts showed a significant reduction in FAZA uptake following treatment with 75 mg/kg/d of gefitinib [tumor to background ratio, 6.1 +/- 1.0 (pretreatment) versus 2.3 +/- 0.6 (posttreatment); P = 0.0004].
  • Similarly, ex vivo quantitation of FAZA uptake showed significantly reduced FAZA uptake in established A431 xenografts treated with gefitinib compared with vehicle control (tumor to blood ratio for controls versus gefitinib, 8.0 +/- 3.0 versus 2.7 +/- 0.8; P = 0.007; or tumor to muscle ratio controls versus gefitinib, 8.6 +/- 2.8 versus 2.6 +/- 1.0; P = 0.002).
  • The effect of gefitinib treatment seemed to be independent of tumor size.
  • In addition, gefitinib treatment reduced pimonidazole-binding in A431 xenografts measured after 5 and 8 days of gefitinib treatment compared with baseline and with tumors treated with vehicle alone.
  • [MeSH-major] Anoxia / radionuclide imaging. Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Lung Neoplasms / radionuclide imaging. Quinazolines / pharmacology. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Animals. Fluorine Radioisotopes / pharmacokinetics. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Nitroimidazoles / pharmacokinetics. Oxidation-Reduction. Oxygen / metabolism. Positron-Emission Tomography. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170034.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fluorine Radioisotopes; 0 / Nitroimidazoles; 0 / Quinazolines; 0 / fluoroazomycin arabinoside; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib; S88TT14065 / Oxygen
  •  go-up   go-down


90. Akers WJ, Zhang Z, Berezin M, Ye Y, Agee A, Guo K, Fuhrhop RW, Wickline SA, Lanza GM, Achilefu S: Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles. Nanomedicine (Lond); 2010 Jul;5(5):715-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles.
  • AIM: Receptor-specific small molecules and nanoparticles are widely used in molecular imaging of tumors.
  • Although some studies have described the relative strengths and weaknesses of the two approaches, reports of a direct comparison and analysis of the two strategies are lacking.
  • Herein, we compared the tumor-targeting characteristics of a small near-infrared fluorescent compound (cypate-peptide conjugate) and relatively large perfluorocarbon-based nanoparticles (250 nm diameter) for imaging alpha(nu)beta(3)-integrin receptor expression in tumors.
  • MATERIALS & METHODS: Near-infrared fluorescent small molecules and nanoparticles were administered to living mice bearing subcutaneous or intradermal syngeneic tumors and imaged with whole-body and high-resolution optical imaging systems.
  • RESULTS: The nanoparticles, designed for vascular constraint, remained within the tumor vasculature while the small integrin-avid ligands diffused into the tissue to target integrin expression on tumor and endothelial cells.
  • Targeted small-molecule and nanoparticle contrast agents preferentially accumulated in tumor tissue with tumor-to-muscle ratios of 8 and 7, respectively, compared with 3 for nontargeted nanoparticles.
  • CONCLUSION: Fluorescent small molecular probes demonstrate greater overall early tumor contrast and rapid visualization of tumors, but the vascular-constrained nanoparticles are more selective for detecting cancer-induced angiogenesis.
  • A combination of both imaging agents provides a strategy to image and quantify integrin expression in tumor tissue and tumor-induced neovascular systems.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Radiol. 2000 Aug;35(8):479-85 [10946975.001]
  • [Cites] Mol Pharm. 2008 Nov-Dec;5(6):1103-10 [19434857.001]
  • [Cites] Circulation. 2002 Nov 26;106(22):2842-7 [12451012.001]
  • [Cites] J Am Chem Soc. 2003 Jul 2;125(26):7766-7 [12822971.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5838-43 [14522907.001]
  • [Cites] Opt Lett. 2003 Nov 1;28(21):2070-2 [14587818.001]
  • [Cites] J Clin Invest. 2004 Jun;113(12):1684-91 [15199403.001]
  • [Cites] Circulation. 2004 Jul 6;110(1):84-90 [15210600.001]
  • [Cites] Magn Reson Med. 2005 Mar;53(3):621-7 [15723405.001]
  • [Cites] Ultrasound Med Biol. 2005 Dec;31(12):1693-700 [16344131.001]
  • [Cites] J Med Chem. 2006 Apr 6;49(7):2268-75 [16570923.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2103-9 [16825592.001]
  • [Cites] Curr Pharm Des. 2006;12(22):2723-47 [16918408.001]
  • [Cites] Curr Opin Biotechnol. 2007 Feb;18(1):11-6 [17241779.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1951-7 [17278104.001]
  • [Cites] Nanomedicine (Lond). 2006 Jun;1(1):17-22 [17716205.001]
  • [Cites] J Nucl Med. 2008 Jan;49(1):1-4 [18077528.001]
  • [Cites] Int J Nanomedicine. 2007;2(4):515-26 [18203420.001]
  • [Cites] Nano Lett. 2008 Apr;8(4):1131-6 [18302330.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] FASEB J. 2008 Aug;22(8):2758-67 [18362202.001]
  • [Cites] Nanomedicine (Lond). 2008 Oct;3(5):703-17 [18817471.001]
  • [Cites] Histochem Cell Biol. 2008 Nov;130(5):845-75 [18825403.001]
  • [Cites] Magn Reson Med. 2008 Dec;60(6):1353-61 [19025903.001]
  • [Cites] FASEB J. 2008 Dec;22(12):4179-89 [18697838.001]
  • [Cites] Invest Radiol. 2009 Jan;44(1):15-22 [18836386.001]
  • [Cites] Angiogenesis. 2009;12(1):17-24 [19067197.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:887-99 [19273106.001]
  • [Cites] Mol Imaging. 2009 Mar-Apr;8(2):101-10 [19397855.001]
  • [Cites] Magn Reson Med. 2000 Sep;44(3):433-9 [10975896.001]
  • (PMID = 20662643.001).
  • [ISSN] 1748-6963
  • [Journal-full-title] Nanomedicine (London, England)
  • [ISO-abbreviation] Nanomedicine (Lond)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109754-03; United States / NCI NIH HHS / CA / R01 CA109754-04; United States / NCI NIH HHS / CA / CA119342-04; United States / NIBIB NIH HHS / EB / R01 EB008111; United States / NCI NIH HHS / CA / CA109754-04; United States / NCI NIH HHS / CA / CA136398-010002; United States / NCI NIH HHS / CA / U54 CA119342; United States / NCI NIH HHS / CA / CA136398-020002; United States / NIBIB NIH HHS / EB / R01 EB008111-01A2; United States / NIBIB NIH HHS / EB / R01 EB008111-02; United States / NCI NIH HHS / CA / U54 CA136398; United States / NCI NIH HHS / CA / CA109754-03; United States / NCI NIH HHS / CA / R01 CA109754-05; United States / NCI NIH HHS / CA / CA109754-05; United States / NCI NIH HHS / CA / CA109754-02; United States / NCI NIH HHS / CA / U54 CA136398-020002; United States / NCI NIH HHS / CA / U54 CA119342-04; United States / NCI NIH HHS / CA / R01 CA109754; United States / NCI NIH HHS / CA / R01 CA109754-01; United States / NCI NIH HHS / CA / CA109754-01; United States / NCI NIH HHS / CA / R01 CA109754-02; United States / NCI NIH HHS / CA / U54 CA136398-010002
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Fluorescent Dyes; 0 / Fluorocarbons; 0 / Indoles; 0 / Integrin alphaVbeta3; 0 / Peptides; 0 / Peptides, Cyclic; 0 / cypate-cyclic(arginyl-glycyl-aspartyl-phenylalanyl-lysyl)
  • [Other-IDs] NLM/ NIHMS220625; NLM/ PMC2914325
  •  go-up   go-down


91. Samadi DB, Chughtai B, Akhavan A, Guru K, Rehman J: Incidental seminal vesicle smooth muscle neoplasm of unknown malignancy following robotic-assisted laparoscopic prostatectomy. Can J Urol; 2008 Jun;15(3):4109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental seminal vesicle smooth muscle neoplasm of unknown malignancy following robotic-assisted laparoscopic prostatectomy.
  • Primary soft tissue sarcomas of the genitourinary tract are rarely seen, especially in the seminal vesicle.
  • While sarcomas have been reported in the seminal vesicle, this is the first report of a smooth muscle neoplasm, of uncertain malignant potential, involving the seminal vesicle.
  • The finding was incidental, following robotic-assisted radical retropubic prostatectomy for prostate cancer.
  • To our knowledge, this is also the first report of a primary seminal vesicle tumor found following radical prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Genital Neoplasms, Male / diagnosis. Laparoscopy. Neoplasms, Multiple Primary. Prostatectomy. Prostatic Neoplasms / surgery. Robotics. Seminal Vesicles. Smooth Muscle Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570719.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


92. Wong E, Kumar V, Howman-Giles RB, Vanderheyden JL: Imaging of therapy-induced apoptosis using (99m)Tc-HYNIC-annexin V in thymoma tumor-bearing mice. Cancer Biother Radiopharm; 2008 Dec;23(6):715-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of therapy-induced apoptosis using (99m)Tc-HYNIC-annexin V in thymoma tumor-bearing mice.
  • The primary focus of this study was to assess the potential of (99m)Tc-HYNIC-Annexin V for in vivo imaging of apoptosis after systemic chemotherapy and "more localized" radiotherapy in nude mice bearing thymoma tumors and correlating it with TUNEL staining. (99m)Tc-HYNIC-Annexin V was administered intravenously to tumor-bearing mice (n = 25) before and after therapy.
  • Tumor uptake increased significantly in response to treatment [chemotherapy (n = 8): 1.80 +/- 0.52 %ID/g, p < 0.009; radiotherapy (n = 7): 0.81 +/- 0.07 %ID/g, p < 0.02], compared to the control group (n = 10) (0.57 +/- 0.05 %ID/g).
  • Tumor-to-muscle (T:M) and tumor-to-blood (T:B) ratios were significantly higher in both chemotherapy-treated (p < 0.02 and p < 0.01) and radiotherapy-treated cohorts (p < 0.05 and p < 0.03), compared to the control cohorts at 4 hours postinjection of (99m)Tc-Annxin V.
  • In the post-therapy cohorts, the immunohistochemistry studies indicated a statistically significant correlation between tumor uptake of (99m)Tc-HYNIC-Annexin V and the extent of apoptosis detected by TUNEL-positive staining (r(2) = 0.41).
  • The results suggest that (99m)Tc-HYNIC-Annexin V may be an ideal agent for imaging apoptosis in response to treatment in a thymoma tumor bearing mouse model.
  • [MeSH-major] Annexin A5. Apoptosis / drug effects. Apoptosis / radiation effects. Organotechnetium Compounds. Radiopharmaceuticals. Thymoma / radionuclide imaging. Thymus Neoplasms / radionuclide imaging
  • [MeSH-minor] Animals. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease Models, Animal. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Radiation, Ionizing. Radiotherapy Dosage. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19111046.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antineoplastic Agents, Alkylating; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m HYNIC annexin V; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


93. Heller LC, Ugen K, Heller R: Electroporation for targeted gene transfer. Expert Opin Drug Deliv; 2005 Mar;2(2):255-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo electroporation, which has previously been used clinically to deliver chemotherapeutic agents, also enhances the delivery of plasmid DNA and has been used to deliver plasmids to several tissue types, particularly muscle and tumour.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16296752.001).
  • [ISSN] 1742-5247
  • [Journal-full-title] Expert opinion on drug delivery
  • [ISO-abbreviation] Expert Opin Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Toxins, Biological; 0 / Vaccines, DNA; 11096-26-7 / Erythropoietin; 187348-17-0 / Interleukin-12
  • [Number-of-references] 129
  •  go-up   go-down


94. Schwartz PE, Kelly MG: Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am; 2006 Mar;33(1):183-98, xii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The possibility that a fibroid may actually be a smooth muscle tumor of uncertain malignant potential or a leiomyosarcoma often dictates the clinical management of rapidly growing fibroids.
  • The clinician must be aware that the infrequent occurrence of uterine leiomyosarcomas makes it difficult to establish absolutely firm recommendations for the diagnosis and management of this disease, particularly with regard to fertility preservation.
  • Nevertheless, this article addresses major issues that a clinician might face in the evaluation of a smooth muscle tumor of the uterus that clinically may be malignant.
  • [MeSH-major] Leiomyoma / pathology. Leiomyosarcoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504815.001).
  • [ISSN] 0889-8545
  • [Journal-full-title] Obstetrics and gynecology clinics of North America
  • [ISO-abbreviation] Obstet. Gynecol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Huang J, Loh KS, Petersson F: Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma. Head Neck Pathol; 2010 Dec;4(4):300-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma.
  • We present a patient (male 54 years) with a history of renal transplant who 14 years post transplantation developed a symptomatic (stridor) laryngeal Epstein Barr virus (EBV)-associated smooth muscle tumor (EBV-SMT) in the absence of concomitant disease elsewhere.
  • Nine years post transplantation the patient developed a subcutaneous EBV-SMT tumor located on the calf.
  • The laryngeal tumor displayed low-grade nuclear atypia and was infiltrating into the surrounding soft tissue, focally ulcerating through the overlying epithelium.
  • Histologic features included: neoplastic cells with myoid differentiation, a component of primitive appearing small mesenchymal cells with hyperchromatic nuclei, mitotic activity, intralesional small to medium sized blood vessels and T-lymphocytes.
  • Both the myoid and small cell mesenchymal components strongly expressed smooth muscle actin and h-caldesmon, but not desmin, cytokeratins, CD34 or S-100 protein.
  • No other tumor was detected on clinical and radiological examinations and no evidence of tumor in other sites, over 8 months of follow-up, till death was detected.
  • This case emphasizes the importance of considering this pathologic entity when solitary smooth muscle actin-expressing tumors are encountered in the larynx of immunocompromised patients.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / virology. Leiomyosarcoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Kidney Transplantation. Larynx / pathology. Larynx / radiography. Male. Middle Aged. Muscle, Smooth / pathology. Muscle, Smooth / radiography. Muscle, Smooth / virology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otolaryngol. 2005 May-Jun;26(3):201-6 [15858778.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):75-82 [16330945.001]
  • [Cites] J Laryngol Otol. 2006 Feb;120(2):e3 [16372993.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):614-21 [10757411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Dec;71(12):4737-41 [4373728.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] J Laryngol Otol. 1995 Jan;109(1):77-9 [7876748.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] N Engl J Med. 1995 Sep 14;333(11):693-8 [7637746.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] J Laryngol Otol. 2008 Jan;122(1):100-4 [17445307.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2008;70(4):264-7 [18487903.001]
  • [Cites] Ear Nose Throat J. 2008 May;87(5):283-7 [18572786.001]
  • [Cites] J Cutan Pathol. 2010 Apr;37(4):507-10 [19615017.001]
  • [Cites] Head Neck. 2010 Nov;32(11):1573-8 [19787794.001]
  • (PMID = 20690046.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2996495
  •  go-up   go-down


96. Ding R, He Y, Xu J, Liu H, Wang X, Feng M, Qi C, Zhang J: Synthesis and biological evaluation of pyrazolo[1,5-a]-pyrimidine-containing 99mTc Nitrido radiopharmaceuticals as imaging agents for tumors. Molecules; 2010;15(12):8723-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and biological evaluation of pyrazolo[1,5-a]-pyrimidine-containing 99mTc Nitrido radiopharmaceuticals as imaging agents for tumors.
  • Biodistribution in tumor-bearing mice demonstrated that the three new complexes showed tumor accumulation, high tumor-to-muscle (T/M) ratios and fast clearance from blood and muscle.
  • Among them, the 99mTcN-MAG-ABCPP showed the most favorable characteristics, with tumor/blood and tumor/ muscle ratios reaching 1.51 and 2.97 at 30 min post-injection, 1.84 and 2.49 at 60 min post-injection, suggesting it could be further studied as potential tumor imaging agent for single photon emission computed tomography (SPECT).
  • [MeSH-major] Neoplasms, Experimental / radiography. Pyrazoles. Pyrimidines. Radiopharmaceuticals. Technetium / chemistry. Tomography, Emission-Computed, Single-Photon / methods

  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119567.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Pyrazoles; 0 / Pyrimidines; 0 / Radiopharmaceuticals; 7440-26-8 / Technetium
  •  go-up   go-down


97. Shi J, Kim YS, Chakraborty S, Jia B, Wang F, Liu S: 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. Bioconjug Chem; 2009 Aug 19;20(8):1559-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics.
  • This report describes the synthesis of MAG(2)-PEG(4)-E[c(RGDfK)](2) (MAG(2)-P-RGD(2): MAG(2) = S-benzoylmercaptoacetylglycylglycyl; PEG(4) = 15-amino-4,7,10,13-tetraoxapentadecanoic acid) and MAG(2)-PEG(4)-E[PEG(4)-c(RGDfK)](2) (MAG(2)-3P-RGD(2)), and the evaluation of (99m)TcO(MAG(2)-P-RGD(2)) and (99m)TcO(MAG(2)-3P-RGD(2)) as new radiotracers for tumor imaging in the athymic nude mice bearing U87MG human glioma xenografts.
  • Biodistribution data in athymic nude mice bearing U87MG human glioma xenografts indicated that replacing the highly charged [(99m)Tc(HYNIC = 6-hydrazinonicotinyl and TPPTS = trisodium triphenylphosphine-3,3',3''-trisulfonate) with smaller (99m)TcO(MAG(2)) resulted in a significant increase in the radiotracer uptake in the tumor and normal organs most likely due to the higher lipophilicity of (99m)TcO(MAG(2)-3P-RGD(2)) (log P = -3.15 ± 0.10) than that for [(99m)Tc(HYNIC-3P-RGD(2))(tricine)(TPPTS)] ((99m)Tc-3P-RGD(2): log P = -3.96 ± 0.05).
  • Even though (99m)TcO(MAG(2)-3P-RGD(2)) has better tumor uptake (15.36 ± 2.17 %ID/g at 60 min postinjection (p.i.
  • ), its tumor-to-background (T/B) ratios (tumor/blood = 13.52 ± 4.57; tumor/liver = 4.25 ± 0.88; tumor/lung = 3.17 ± 0.60; and tumor/muscle = 8.34 ± 2.34) are not as good as those of (99m)Tc-3P-RGD(2) (tumor/blood = 36.0 ± 11.5; tumor/liver = 5.14 ± 1.46; tumor/lung = 4.36 ± 0.54; and tumor/muscle = 13.70 ± 2.21) at 60 min p.i.

  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):530-7 [17373771.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6610-6 [18006761.001]
  • [Cites] Nucl Med Biol. 2008 Jan;35(1):111-21 [18158950.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):201-10 [18069778.001]
  • [Cites] Bioconjug Chem. 2008 Mar;19(3):634-42 [18281926.001]
  • [Cites] J Nucl Med. 2008 Apr;49(4):511-4 [18375921.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1100-8 [18204838.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):879-86 [18483090.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S [18523069.001]
  • [Cites] Int J Cancer. 2000 Aug 20;90(4):186-98 [10993959.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):326-36 [11216533.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1781-5 [11280722.001]
  • [Cites] J Nucl Med. 2005 Aug;46(8):1333-41 [16085591.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10):1707-18 [16204722.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1580-8 [16287258.001]
  • [Cites] Drugs R D. 2008;9(6):351-68 [18989988.001]
  • [Cites] Curr Pharm Des. 2008;14(28):2943-73 [18991712.001]
  • [Cites] J Med Chem. 2008 Dec 25;51(24):7980-90 [19049428.001]
  • [Cites] J Nucl Med. 2009 Jan;50(1):116-22 [19091899.001]
  • [Cites] Mol Pharm. 2009 Jan-Feb;6(1):231-45 [19067525.001]
  • [Cites] Bioconjug Chem. 2009 Apr;20(4):750-9 [19320477.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):113-21 [16391195.001]
  • [Cites] Mini Rev Med Chem. 2006 Feb;6(2):227-34 [16472190.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):431-4 [16475729.001]
  • [Cites] Chem Biol Drug Des. 2006 Feb;67(2):115-26 [16492159.001]
  • [Cites] Bioconjug Chem. 2006 Jul-Aug;17(4):1069-76 [16848417.001]
  • [Cites] Curr Pharm Des. 2006;12(22):2723-47 [16918408.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):472-87 [17009846.001]
  • [Cites] Appl Radiat Isot. 2007 Jan;65(1):70-8 [17011200.001]
  • [Cites] Bioconjug Chem. 2006 Nov-Dec;17(6):1499-507 [17105229.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] Nucl Med Biol. 2006 Nov;33(8):945-52 [17127166.001]
  • [Cites] Nucl Med Biol. 2007 Jan;34(1):29-35 [17210459.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):267-73 [16909226.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):438-46 [17341108.001]
  • [Cites] Bioconjug Chem. 2001 Jul-Aug;12(4):559-68 [11459461.001]
  • [Cites] Q J Nucl Med. 2001 Jun;45(2):179-82 [11476168.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 May;29(5):699-709 [11976811.001]
  • [Cites] Bioconjug Chem. 2002 May-Jun;13(3):561-70 [12009947.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6146-51 [12414640.001]
  • [Cites] Cancer Biother Radiopharm. 2002 Dec;17(6):641-6 [12537667.001]
  • [Cites] Chemistry. 2003 Jun 16;9(12):2717-25 [12772286.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):41-9 [14733582.001]
  • [Cites] Nucl Med Biol. 2004 Jan;31(1):11-9 [14741566.001]
  • [Cites] Nuklearmedizin. 2004 Feb;43(1):26-32 [14978538.001]
  • [Cites] Nucl Med Biol. 2004 Feb;31(2):179-89 [15013483.001]
  • [Cites] Curr Pharm Des. 2004;10(13):1439-55 [15134568.001]
  • [Cites] J Nucl Med. 2004 May;45(5):892-902 [15136641.001]
  • [Cites] Mol Imaging. 2004 Apr;3(2):96-104 [15296674.001]
  • [Cites] Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 [15380745.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Aug;19(4):399-404 [15453954.001]
  • [Cites] Bioconjug Chem. 1996 Mar-Apr;7(2):196-202 [8983341.001]
  • [Cites] Eur J Nucl Med. 1998 Oct;25(10):1383-9 [9818277.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1536-44 [17704249.001]
  • (PMID = 19603780.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115883 A2; United States / NHLBI NIH HHS / HL / R21 HL083961; United States / NCI NIH HHS / CA / R01 CA115883; United States / NHLBI NIH HHS / HL / R21 HL083961-02; United States / NCI NIH HHS / CA / CA115883-03; United States / NCI NIH HHS / CA / R01 CA115883-03; United States / NHLBI NIH HHS / HL / R21 HL083961-01; United States / NHLBI NIH HHS / HL / HL083961-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Dipeptides; 0 / Peptides, Cyclic; 0 / S-benzoylmercaptoacetylglycylglycyl; 0 / cyclic arginine-glycine-aspartic acid peptide; 7440-26-8 / Technetium
  • [Other-IDs] NLM/ NIHMS132874; NLM/ PMC2888811
  •  go-up   go-down


98. Mercer SE, Friedman E: Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival. Cell Biochem Biophys; 2006;45(3):303-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival.
  • Dyrk family kinases are highly conserved mediators of growth control and differentiation.
  • Mirk is expressed at high levels in skeletal muscle; thus, most of the recent studies of Mirk have used myogenesis as a model system to explore the function of Mirk in a native physiological environment.
  • These studies have revealed that Mirk is a multifunctional Ser/Thr kinase that plays a critical role in muscle differentiation by regulatory effects on motility, transcription, cell cycle progression, and cell survival.
  • Mirk also is found at elevated levels in various solid tumors, where it seems to act as a tumor survival factor.
  • This review summarizes the known regulators and functions of Mirk kinase and outlines opportunities for future studies of Mirk in the fields of muscle and tumor biology.
  • [MeSH-major] Apoptosis / physiology. Apoptosis Regulatory Proteins / chemistry. Apoptosis Regulatory Proteins / metabolism. Cell Differentiation / physiology. Cell Survival / physiology. Mitogen-Activated Protein Kinases / chemistry. Mitogen-Activated Protein Kinases / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845176.001).
  • [ISSN] 1085-9195
  • [Journal-full-title] Cell biochemistry and biophysics
  • [ISO-abbreviation] Cell Biochem. Biophys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA67405
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Transcription Factors; EC 2.7.1.- / Dyrk kinase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Number-of-references] 99
  •  go-up   go-down


99. Ramaprasad S, Ripp E, Missert J, Pandey RK: In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model. Curr Drug Discov Technol; 2007 Aug;4(2):126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model.
  • This process is studied by (19)F in vivo MR methodology in a murine tumor model.
  • The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum.
  • The mice were injected with a solution of approximately 100 micro-moles of the fluorinated photosensitizer and the (19)F MR examination of the photosensitizer in the tumor or the muscle was performed.
  • [MeSH-major] Fibrosarcoma / metabolism. Neoplasms, Experimental / metabolism. Photosensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Fluorine. Magnetic Resonance Imaging. Mice

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691914.001).
  • [ISSN] 1570-1638
  • [Journal-full-title] Current drug discovery technologies
  • [ISO-abbreviation] Curr Drug Discov Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 284SYP0193 / Fluorine
  •  go-up   go-down


100. Ducès A, Karaky R, Martel-Renoir D, Mir L, Hamma-Kourbali Y, Biéche I, Opolon P, Delbé J, Courty J, Perricaudet M, Griscelli F: 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development. Mol Cancer Ther; 2008 Sep;7(9):2817-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 16-kDa fragment of pleiotrophin acts on endothelial and breast tumor cells and inhibits tumor development.
  • Pleiotrophin (PTN) is a 136-amino acid secreted heparin-binding protein that is considered as a rate-limiting growth and an angiogenic factor in the onset, invasion, and metastatic process of many tumors.
  • We investigated a new strategy consisting in evaluating the antitumor effect of a truncated PTN, lacking the COOH-terminal 111 to 136 portion of the molecule (PTNDelta111-136), which may act as a dominant-negative effector for its mitogenic, angiogenic, and tumorigenic activities by heterodimerizing with the wild-type protein.
  • In vitro studies showed that PTNDelta111-136 selectively inhibited a PTN-dependent MDA-MB-231 breast tumor and endothelial cell proliferation and that, in MDA-MB-231 cells expressing PTNDelta111-136, the vascular endothelial growth factor-A and hypoxia-inducible factor-1alpha mRNA levels were significantly decreased by 59% and 71%, respectively, compared with levels in wild-type cells.
  • In vivo, intramuscular electrotransfer of a plasmid encoding a secretable form of PTNDelta111-136 was shown to inhibit MDA-MB-231 tumor growth by 81%.
  • This antitumor effect was associated with the detection of the PTNDelta111-136 molecule in the muscle and tumor extracts, the suppression of neovascularization within the tumors, and a decline in the Ki-67 proliferative index.
  • Because PTN is rarely found in normal tissue, our data show that targeted PTN may represent an attractive and new therapeutic approach to the fight against cancer.
  • [MeSH-major] Breast Neoplasms / pathology. Carrier Proteins / pharmacology. Cytokines / pharmacology. Endothelial Cells / drug effects. Peptide Fragments / pharmacology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Down-Regulation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Mice. Mice, Nude. Molecular Weight. Mutant Proteins / metabolism. Neovascularization, Pathologic / pathology. Receptors, Cell Surface / metabolism. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790762.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cytokines; 0 / Mutant Proteins; 0 / Peptide Fragments; 0 / Receptors, Cell Surface; 134034-50-7 / pleiotrophin
  •  go-up   go-down






Advertisement